Methods for targeting pharmaceutically active ingredients in total knee arthroplasty
By delivering NSAIDs locally with biodegradable triblock and diblock copolymers after total knee arthroplasty, the challenges of pain and inflammation management after TKR have been addressed, resulting in reduced opioid dependence and improved patient recovery.
Patent Information
- Application Number
- CN202580029533.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-10-16
- Filing Date
- 2025-04-25
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies are insufficient to effectively manage pain and inflammation following total knee replacement (TKR), especially after patients are discharged, leading to opioid dependence and chronic pain problems. Furthermore, systemic exposure to traditional NSAIDs carries the risk of cardiovascular and gastrointestinal complications.
Using biodegradable triblock and diblock copolymers as a drug delivery system, combined with nonsteroidal anti-inflammatory drugs (NSAIDs), it achieves continuous pain and inflammation management by local application to the knee joint, reducing systemic exposure.
It effectively reduces the use of opioids, lowers pain and inflammation, shortens recovery time, improves patients' quality of life, and reduces the need for complications and revision surgery.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention relates to a method for treating or managing pain or inflammation in patients following total knee arthroplasty (TKR), particularly first-time TKR patients, by administering a biodegradable drug delivery composition comprising an NSAID, a triblock copolymer containing a polyester and polyethylene glycol, and a diblock copolymer containing a polyester and a capped polyethylene glycol. Background Technology
[0002] Osteoarthritis (OA) is the most common type of joint disease, affecting more than 20 million people in the United States alone. OA is a degenerative disease caused by the biochemical breakdown of articular (hyaline) cartilage in the synovial joint. Although research on osteoarthritis drugs has attempted to find non-surgical solutions to this challenging condition, most efforts have been unsuccessful, making total knee replacement (TKR) the most viable treatment option.
[0003] In 2014, approximately 680,150 total knee replacements (TKRs) were performed in the United States, and this number is projected to increase by 85% to 1.26 million annually by 2030. [M. Sloan, A. Premkumar, NP Sheth, Projected Volume of Primary Total Joint Arthroplasty in the US, 2014 to 2030, The Journal of Bone and joint surgery. [American Volume 100(17) (2018) 1455-1460.] Safely and effectively managing pain after such invasive surgery remains a significant clinical challenge and directly impacts length of hospital stay, recovery success rate, and overall patient recovery time. Complete removal of cartilage and bone, adhesion of large prosthetic implants to bone, and contusions and soreness of associated soft tissues are all accompanied by excessive levels of pain, inflammation, swelling, and bleeding.
[0004] Although total knee replacement (TKR) is widely considered the gold standard for treating end-stage knee disease, it is believed that approximately 20% of TKR patients experience chronic pain, complications, and adverse clinical outcomes (Scott, CE, Howie, CR, MacDonald, D., and Biant, LC (2010) Predicting dissatisfaction following total knee replacement: a prospective study of 1217 patients). The Journal of Bone and joint surgery.(British volume 92, 1253-1258). These adverse outcomes may stem from poor postoperative pain and inflammation control, often requiring revision surgery. Revision surgery, due to its complexity, cost, and high complication rate, can severely impair quality of life and increase a significant socioeconomic burden.
[0005] Although the trauma associated with TKR surgery changes very little over time, improvements in acute-phase analgesia standards using a multimodal approach have led to shorter hospital stays and earlier patient discharges (near same-day discharge). Unfortunately, once patients are no longer under hospital monitoring and support at home, they often experience severe pain and inflammation after the perioperative analgesia wears off, and most require at least 6 weeks of opioid analgesia [EC Sun, BD Darnall, LC Baker, S. Mackey, Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period, JAMA Intern Med 176(9) (2016) 1286-93; R. Fuzier, I. Serres, R. Bourrel, A. Palmaro, JL Montastruc, M.Lapeyre-Mestre, Analgesic drug consumption increases after knee arthroplasty: a pharmacoepidemiological study investigating postoperative pain, Pain 155(7)(2014) 1339-45].
[0006] Therefore, TKR surgery has the highest demand for opioid prescriptions among all surgical procedures [M. Mundkur, Background and Rationale for the Development of Opioid-Sparing and Opioid-Replacement Drugs, Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)According to the FDA, 2018, this is also the pathway by which 15% of TKR patients become addicted to opioids [P. Pharmaceuticals, Exposing a silent gateway to persistent opioiduse: A choices matter status report, 2018], representing nearly 144,000 Americans in 2021 alone (according to [M. Sloan, A. Premkumar, NP Sheth, Projected Volume of Primary Total Joint Arthroplasty in the US, 2014 to 2030]). The Journal of Bone and joint surgery. (Data calculations from American volume 100(17) (2018) 1455-1460).
[0007] Inflammation is the body's response to injury and is inherently a beneficial event that promotes the recovery of tissue structure and physiological function. The typical outcome of an acute inflammatory process is successful resolution and repair of tissue damage. Alternatively, failure of acute inflammation to resolve (or improper management) can lead to poor wound healing, joint fibrosis, pain, and loss of function. [E. Ricciotti, GA FitzGerald, Prostaglandins and inflammation, Arteriosclerosis Thrombosis, and Vascular Biology 31(5) (2011) 986-1000].
[0008] Prostaglandins (PGs) play a crucial role in the generation of inflammatory responses. [E. Ricciotti, GAFitzGerald, Prostaglandins and inflammation, Arteriosclerosis, Thrombosis, and Vascular Biology[31(5) (2011) 986-1000] These are produced from arachidonic acid by the action of cyclooxygenase isoenzymes COX-1 and COX-2, and their biosynthesis is blocked by nonsteroidal anti-inflammatory drugs (NSAIDs), including those that selectively inhibit COX-2. PG production is generally very low in non-inflammatory tissues, but their biosynthesis increases significantly in inflamed tissues. PG contributes to the development of acute inflammation, leukocyte recruitment, and immune cell infiltration. During inflammation, prostaglandin E2 (PGE2) is of particular interest because it is involved in all the processes leading to the typical signs of inflammation (redness, swelling, and pain). Cyclooxygenase-2 (COX-2) appears to be a major driver of prostaglandin formation in inflammation, and its expression in inflamed tissues provides a theoretical basis for the development of NSAIDs designed to selectively inhibit COX-2. Therefore, COX-2 inhibitors, including celecoxib, have been developed and used in a wide range of clinical pain management. [MH Zemmel, The role of COX-2 inhibitors in the perioperative setting: efficacy and safety——a systematic review, AANA J 74(1)(2006) 49-60] Celecoxib was first approved by the FDA in 1998 as an oral capsule formulation, Celebrex (Pfizer, 1998). It is indicated for the relief of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, acute pain, and dysmenorrhea. However, the use of oral NSAIDs may have both short-term and long-term adverse consequences. In the short term, COX-2 inhibitors may increase the risk of postoperative bleeding by adverse interactions with drugs used to prevent deep vein thrombosis (DVT). In addition, long-term systemic exposure to COX-2 inhibitors increases the risk of cardiovascular, gastrointestinal, and hypertensive complications. [LG Howes, Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?] Therapeutics and Clinical Risk Management 3(5) (2007) 831-45; D. Clemett, KL Goa, Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain, Drugs 59(4) (2000) 957-80].
[0009] Therefore, there remains a need in the art to deliver non-opioid pharmaceutically active ingredients directly to the knee joint (particularly for pain and inflammation management) and to prolong the duration of local action through sustained delivery, while limiting systemic exposure and eliminating the need for chronic oral administration.
[0010] Therefore, there remains a need to provide methods for managing or treating pain and / or inflammation after TKR. There is also a need to improve patient rehabilitation after TKR.
[0011] These and other objectives are achieved by the present invention, as demonstrated by the overview of the invention, the description of preferred embodiments, and the claims. Summary of the Invention
[0012] This invention provides a method for treating or managing pain or inflammation in a patient following total knee arthroplasty (TKR), the method comprising administering a biodegradable drug delivery composition to the patient's knee joint, the composition comprising:
[0013] (a) Biodegradable triblock copolymers having the following formula:
[0014] PLA v -PEG w -PLA x
[0015] In the formula, v and x are the number of repeating units ranging from 24 to 682, w is the number of repeating units ranging from 4 to 273, and v = x or v ≠ x;
[0016] (b) Biodegradable diblock copolymers having the following formula:
[0017] mPEG y -PLA z
[0018] In the formula, y and z are the number of repeating units, with y ranging from 3 to 68 and z ranging from 7 to 327.
[0019] In the biodegradable pharmaceutical composition, the ratio of the biodegradable triblock copolymer in (a) to the biodegradable diblock copolymer in (b) is from 3:2 to 1:19; and
[0020] (c) Nonsteroidal anti-inflammatory drugs (NSAIDs).
[0021] Preferably, the patient has not previously received TKR, i.e., the present invention relates to a method for treating or managing pain or inflammation in a patient receiving TKR for the first time using a biodegradable drug delivery system.
[0022] In another aspect, the present invention provides a method for treating or managing pain or inflammation in a patient after TKR, the method comprising administering a biodegradable drug delivery composition to the patient's knee joint, the composition comprising:
[0023] (a) Biodegradable triblock copolymers having the following formula:
[0024] PLA v -PEG w -PLA x
[0025] In the formula, v and x are the number of repeating units ranging from 24 to 682, w is the number of repeating units ranging from 4 to 273, and v = x or v ≠ x;
[0026] (b) Biodegradable diblock copolymers having the following formula:
[0027] mPEG y -PLA z
[0028] In the formula, y and z are the number of repeating units, with y ranging from 3 to 68 and z ranging from 7 to 327.
[0029] In the biodegradable pharmaceutical composition, the ratio of the biodegradable triblock copolymer in (a) to the biodegradable diblock copolymer in (b) is from 3:2 to 1:19; and
[0030] (c) Nonsteroidal anti-inflammatory drugs (NSAIDs)
[0031] The patient had not previously received TKR.
[0032] Typically, in the formulation, the NSAID is present in an amount of 1% to 85% (w% / w%), 1% to 60% (wt% / wt%), or 10% to 60% (wt% / wt%), or 10% to 30% (wt% / wt%), or 10% to 20% (wt% / wt%), or about 15% (wt% / wt%) of the total composition.
[0033] In one embodiment, the molecular weight of the polyethylene glycol chains in the triblock copolymer and / or diblock copolymer ranges from 300 Da to 12 kDa, or 1 kDa to 8 kDa, or 1 kDa to 5 kDa, or 1 kDa to 2 kDa. In one embodiment, the molecular weight of the polyethylene glycol chains in the triblock copolymer and / or diblock copolymer is 1.5 to 2.5 kDa. In one embodiment, the molecular weight of the polyethylene glycol chains in the triblock copolymer and / or diblock copolymer is about 2 kDa.
[0034] In one embodiment, the molar ratio of lactic acid to ethylene oxide in the triblock copolymer is 1.6 to 7.2, or 1.6 to 5.0, or 1.6 to 3.0, or about 2.0.
[0035] In one embodiment, the molar ratio of lactic acid to ethylene oxide in the diblock copolymer is 1.6 to 7.2, or 1.6 to 5.0, or 1.9 to 4.8, or 1.9 to 3.0, or about 2.4.
[0036] In one embodiment, the molar ratio of lactic acid to ethylene oxide in the triblock copolymer is 1.6 to 7.2, and the molar ratio of lactic acid to ethylene oxide in the diblock copolymer is 1.9 to 4.8.
[0037] Typically, the degree of polymerization in the triblock copolymer is 92 to 135, and the degree of polymerization in the diblock copolymer is 91 to 180; or, the degree of polymerization in the triblock copolymer is 95 to 130, and the degree of polymerization in the diblock copolymer is 95 to 175; or, the degree of polymerization in the triblock copolymer is 99 to 132, and the degree of polymerization in the diblock copolymer is 95 to 175; or, the degree of polymerization in the triblock copolymer is 100 to 170, and the degree of polymerization in the diblock copolymer is 115 to 195.
[0038] In one embodiment, the triblock copolymer is present in an amount of 2% to 45% (wt% / wt%), or 6% to 24% (wt% / wt%), or 6% to 15% (wt% / wt%), 6% to 10% (wt% / wt%), or about 8% (wt% / wt%) of the total composition.
[0039] In one embodiment, the diblock copolymer is present in an amount of 8% to 50% (wt% / wt%), or 12% to 40% (wt% / wt%), or 20% to 40% (wt% / wt%), or about 32% (wt% / wt%) of the total composition.
[0040] In one embodiment, the triblock copolymer is present in an amount of 6% to 24% (wt% / wt%) of the total composition, and the diblock copolymer is present in an amount of 12% to 40% (wt% / wt%) of the total composition. Typically, the total polymer content is 20% to 50% (w% / w%), or 30% to 50% (w% / w%), or about 40% (w% / w%) of the total composition.
[0041] In one embodiment, the total polymer content is 30% to 50% (w% / w%) of the total composition, and the NSAID is present in an amount of 10% to 20% (w% / w%) of the total composition.
[0042] Preferably, the composition further comprises a pharmaceutically acceptable carrier. Typically, the pharmaceutically acceptable carrier is a biocompatible organic solvent. The biocompatible organic solvent may be selected from: benzyl alcohol, benzyl benzoate, dimethyl isosorbide (DMI), dimethyl sulfoxide (DMSO), ethyl acetate, ethyl benzoate, ethyl lactate, glycerol formaldehyde, methyl ethyl ketone, methyl isobutyl ketone, N-ethyl-2-pyrrolidone, N-methyl-2-pyrrolidone (NMP), pyrrolidone-2, tetraethylene glycol, triacetin, glyceryl tartrate, tributyrate, tripropionate (tripro), and mixtures thereof. In one embodiment, the solvent is DMSO, tripro, NMP, and mixtures thereof, preferably DMSO.
[0043] In one embodiment, the NSAID may be at least one of the following: etofenamate, celecoxib, apricoxib, rofecoxib, nabumetone, benorilate, etoricoxib, ampiroxicam, aminophemazone, valdecoxib, acetominophen, bufexamac, nimesulide, parecoxib, mefenamic acid. dexbuprofen, ibuprofen, flurbiprofen, aspirin, dexketoprofen, diclofenac, diflunisal, etodolac, fenoprofen, firocoxib, indomethacin, ketoprofen, ketorolac, lornoxicam, loxoprofen, loxomac, lumiracoxib, meclofenamic acid The NSAIDs include meloxicam, naproxen, Naprosyn, nimalox, oxaporozin, piroxicam, salsalate, sulindac, tenoxicam, tolfenamic acid, and ropivicaine. Preferably, the NSAID is celecoxib.
[0044] In one embodiment, the composition comprises celecoxib in an amount of 13% to 17% (wt% / wt%) of the total composition, a triblock copolymer in an amount of 7% to 9% (wt% / wt%) of the total composition, a diblock copolymer in an amount of 30% to 34% (wt% / wt%) of the total composition, and dimethyl sulfoxide in an amount of 43% to 47% (wt% / wt%) of the total composition.
[0045] In one embodiment, the formulation of the biodegradable pharmaceutical composition is prepared by mixing a triblock copolymer and a diblock copolymer in a biocompatible organic solvent to form a mixture of the triblock copolymer and the diblock copolymer, and then adding NSAID to the mixture of the triblock copolymer and the diblock copolymer. In one embodiment, the solvent is removed by evaporation.
[0046] In one embodiment, the mixture of the triblock copolymer and the diblock copolymer is further exposed to an aqueous liquid to form solid clumps.
[0047] Typically, the composition is administered to the patient in volumes of 0.1 to 6 mL, 2 to 5 mL, or 3 to 4 mL. Typically, the celecoxib concentration of the composition is from about 150 mg / mL to about 200 mg / mL, or from about 170 to about 190 mg / mL.
[0048] Typically, the maximum celecoxib plasma concentration reached 24 hours after a single administration of the composition is less than 200 ng / mL, optionally less than 180 ng / mL, and optionally less than 160 ng / mL.
[0049] Typically, therapeutically effective concentrations of NSAID are released over a period of at least 4 weeks, preferably at least 6 weeks, and most preferably at least 8 weeks after TKR.
[0050] Typically, the composition is a liquid that can be injected into the knee joint, or a solid particle that can be injected into the knee joint, or a rod-shaped implant or spatial formulation.
[0051] Optionally, the method also includes administering standardized multimodal analgesia.
[0052] Standardized multimodal analgesia may comprise two or more active pharmaceutical ingredients selected from the following: bupivacaine, ropivacaine, lidocaine, acetaminophen, methocarbamol, pregabalin, gabapentin, ketamine, morphine, oxycodone, hydrocodone, hydromorphone, fentanyl, tramadol, tapentadol, nerve blockers, and dexamethasone. In one embodiment, standardized multimodal analgesia comprises bupivacaine hydrochloride, acetaminophen, and methocarbamol.
[0053] Two or more active pharmaceutical ingredients may be administered simultaneously with, separately from, or sequentially with a biodegradable drug delivery composition.
[0054] Optionally, bupivacaine can be administered via periarticular infiltration. For subjects weighing less than 80 kg, a mixture of 0.25% bupivacaine with adrenaline (1:200,000) and 0.25% bupivacaine without adrenaline at a ratio of 2:1 can be used. For subjects weighing more than 80 kg, a mixture of 0.25% bupivacaine with adrenaline (1:200,000) and 0.25% bupivacaine without adrenaline at a ratio of 3:1 can be used. The dosage is 1 mL / kg and a maximum of 90 mL.
[0055] Standardized multimodal analgesia typically includes an opioid; optionally, the opioid is selected from morphine, oxycodone, hydrocodone, hydromorphone, fentanyl, tramadol, tapentadol, and combinations thereof, or the opioid is morphine and / or oxycodone.
[0056] In one implementation, the average cumulative opioid consumption of the patient is reduced compared to patients who receive only standardized multimodal analgesia containing opioids; optionally, the reduction occurs 2 weeks to 90 days after TKR, or within 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, or 90 days after TKR.
[0057] In one implementation, when analyzing all patients, cumulative opioid consumption was reduced by 15% to 20% 90 days after TKR. In another implementation, for patients who had not previously received TKR, cumulative opioid consumption was reduced by 25% to 30% 90 days after TKR.
[0058] In one implementation, the patient’s daily opioid consumption is reduced compared to a patient receiving only standardized multimodal analgesia containing opioids; optionally, the daily opioid consumption is reduced from 2 weeks to 90 days after TKR, or within 2 weeks, 4 weeks, 6 weeks, 12 weeks, or 90 days after TKR.
[0059] Typically, average cumulative opioid consumption or daily opioid consumption is measured in morphine milligram equivalents (MME).
[0060] In one implementation, the area under the curve (AUC) of the numerical rating scale (NRS) pain score is reduced at 3, 7, 2, 6, or 90 days after TKR, compared to patients receiving only standardized multimodal analgesia. Optionally, the reduction is calculated based on the least-squares mean of the NRS AUC. In one implementation, the least-squares mean of the NRS pain score AUC can be reduced by at least 3%, optionally at least 4%, optionally at least 5%, and optionally at least 6%, compared to patients receiving only standardized multimodal analgesia. In patients who have not previously received TKR, the least-squares mean of the NRS pain score AUC can be reduced by at least 8%, optionally at least 9%, optionally at least 10%, optionally at least 12%, optionally at least 14%, and optionally at least 16%, compared to patients receiving only standardized multimodal analgesia.
[0061] In one implementation, the AUC of the Numerical Rating Scale (NRS) pain score is statistically adjusted based on opioid consumption.
[0062] In one implementation, the least squares mean of the visual analog scale for pain is reduced at 2 weeks, 6 weeks, or 90 days after TKR, relative to patients who only receive standardized multimodal analgesia; optionally, the reduction is at least 10% difference in the least squares mean of the VAS, optionally at least 20% difference.
[0063] In one implementation, compared to patients who only receive standardized multimodal analgesia, the time it takes for patients to achieve a range of motion of 100 to 110 degrees of knee joint is shortened.
[0064] In another implementation, the patient’s range of motion (ROM) improved 1 week to 3 months after TKR compared to the patient receiving only standardized multimodal analgesia; or improved ROM at 1 week, 2 weeks, 3 weeks, 6 weeks, or 12 weeks after TKR; optionally, at 3 months after TKR, ROM improved by 5% to 10% compared to the patient receiving only standardized multimodal analgesia.
[0065] In one implementation, the patient's knee joint effusion is reduced, and the knee joint effusion is measured as a percentage difference in circumference between the knee that has undergone TKR and the contralateral knee, as well as between the knee that has undergone TKR and a patient who has only received standardized multimodal analgesia; optionally, the measurement is performed 2 weeks, 6 weeks, or 3 months after TKR.
[0066] In another implementation, the patient’s activity level improved as measured by a timed stand-up walking test, which measures the time required for the patient to stand up, walk 3 meters (10 feet), turn around, walk back and sit down again, compared to a patient who only received standardized multimodal analgesia. Optionally, the timed stand-up walking test results were measured 2 weeks, 6 weeks or 3 months after TKR.
[0067] In one implementation, the Physical Component Summary (SF-12v2) score of the Summary Health Survey is at least 15% or at least 30% higher than that of patients who receive only standardized multimodal analgesia.
[0068] In yet another embodiment, compared to patients receiving only standardized multimodal analgesia, the patient's health status improved as measured by the EuroQoL 5D (EQ-5D-5L) index at 2 weeks post-TKR; optionally, the index increased by at least 70 or at least 85 compared to patients receiving only standardized multimodal analgesia. In one embodiment of the invention, in patients who had not previously received TKR, the index at 2 weeks post-TKR increased by at least 150 or at least 170 compared to patients receiving only standardized multimodal analgesia.
[0069] In one implementation, patients who received standardized multimodal analgesia alone showed improvement in their 2011 Knee Society Score (KSS2011) measured 2 weeks after TKR; optionally, their KSS2011 patient satisfaction and / or functional activity scores increased by at least 30%, at least 40%, or at least 50% compared to patients who received standardized multimodal analgesia alone. Patients who had not previously received TKR typically showed an increase in KSS2011 patient satisfaction and / or functional activity scores of at least 40%, at least 50%, or at least 60% compared to patients who received standardized multimodal analgesia alone.
[0070] In one embodiment, the biodegradable drug delivery composition is drawn into a syringe for administration and injected into the knee joint; or, the formulation is manually formed into a solid mass by exposing it to an aqueous liquid and manually placing it into the knee joint.
[0071] In one embodiment, the biodegradable drug delivery composition is subjected to mechanical forces. Typically, these mechanical forces are generated by the internal structure of the joint, joint movement, weight-bearing, and / or synovial fluid pressure.
[0072] In another aspect, the present invention provides a composition for use in the method as defined above.
[0073] In the method described above for treating or managing pain or inflammation following TKR, a biodegradable drug delivery formulation can be fragmented by subjecting the biodegradable drug delivery formulation to mechanical action (e.g., mechanical action generated by the internal structures of the knee joint, joint movement, weight-bearing, and / or synovial pressure). In this method, the biodegradable drug delivery formulation is broken down into fragments (i.e., fragmented).
[0074] Other aspects and implementation methods are set forth below, or will be readily derived from the following description of preferred embodiments. Attached Figure Description
[0075] Figure 1 The plasma concentration of celecoxib over time is shown.
[0076] Figure 2 The VAS least squares mean pain score is shown for all patients in the phase 2 clinical trial, with patients receiving the F14 formulation combined with standardized multimodal analgesia (MMA) (solid line) and patients receiving MMA alone (dashed line) during the 90-day period.
[0077] Figure 3The graph shows the range of activity (ROM) in degrees over time for all patients in the phase 2 clinical trial who received the F14 formulation in combination with standardized multimodal analgesia (MMA) (solid line) and those who received MMA alone (dashed line).
[0078] Figure 4 This study shows the percentage difference in AUC NRS pain scores between patients who received the F14 formulation combined with standardized multimodal analgesia (MMA) and those who received MMA alone, for patients who had not previously received TKR, after statistical adjustment based on opioid consumption.
[0079] Figure 5 The graph shows the mean cumulative opioid consumption over time in morphine milligram equivalents (MME) for all patients (top) and patients who had not previously received TKR (bottom), patients receiving F14 formulation combined with standardized multimodal analgesia (MMA) (black circle) and patients receiving MMA only (white circle).
[0080] Figure 6A The graph shows the change in knee range of motion (ROM) over time in degrees for all patients in the phase 3 clinical trial (top) or only patients who had not previously received TKR (bottom), patients receiving the F14 formulation combined with standardized multimodal analgesia (MMA) (black circle) and patients receiving MMA only (white circle).
[0081] Figure 6B yes Figure 6A The enlarged version of the figure below shows the ROM (mean ROM) of patients who have not previously received TKR over a period of 2 to 12 weeks. The baseline ROM required for recovery is shown by dashed lines.
[0082] Figure 6C A diagram showing how to measure ROM is provided.
[0083] Figure 7 This is a graph showing the change over time in knee effusion (percentage difference in circumference compared to the contralateral knee) for all patients (top) or only patients who have not previously received TKR (bottom), patients receiving F14 formulation combined with standardized multimodal analgesia (MMA) (black circle) and patients receiving MMA only (white circle).
[0084] Figure 8 The graph shows the time taken for the Timed Stand-Up-Walk (TUG) test over time for all patients (top) or only patients who have not previously received TKR (bottom), patients receiving the F14 formulation combined with standardized multimodal analgesia (MMA) (squares) and patients receiving MMA only (circles). Detailed Implementation
[0085] As used herein, the term "biodegradable" means that triblock copolymers and diblock copolymers will erode, degrade, or break down in vivo over time to form smaller, non-toxic components.
[0086] The term "animal" encompasses all members of the animal kingdom.
[0087] As used herein, mammals encompass any group of vertebrates whose females possess glands that secrete milk, including humans. Examples of mammals include, but are not limited to, cats, dogs, humans, pigs, horses, cattle, apes, chimpanzees, etc.
[0088] "Active ingredient" or "active pharmaceutical ingredient" means a medicine or agent used to treat or manage a condition or disease or its symptoms (specifically, pain or inflammation following TKR in this application). Therefore, active ingredient, medicine, and agent are used interchangeably. As used herein, the term medicine or active ingredient includes, but is not limited to, substances having physiological or pharmacological activity that act locally or systemically in an animal. At least one active ingredient is present in the biodegradable pharmaceutical composition used in the methods of this invention. More than one active ingredient may be used in the methods of this invention, such as nonsteroidal anti-inflammatory drugs and local anesthetics.
[0089] Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of drugs used as antipyretics, anti-inflammatory agents, and analgesics. These effects make NSAIDs suitable for treating pain and inflammation following transarterial keratolysis (TKR).
[0090] NSAIDs are typically classified according to their chemical structure and selectivity: acetylated salicylates (aspirin), non-acetylated salicylates (diflunisal, disalicylate), propionic acids (naproxen, ibuprofen), acetic acids (diclofenac, indomethacin), enolates (meloxicam, piroxicam), anthranilates (meclofenamic acid, mefenamic acid), naphthylalanine (nabumetone), and selective COX-2 inhibitors (celecoxib, etoricoxib, romecoxib, rofecoxib, vardicoxib).
[0091] The term "implant" refers to a drug delivery composition that is injectable, in-situ formed, and biodegradable, and becomes a solid implant upon contact with an aqueous fluid after being injected into the intra-articular space. Therefore, the synthesized formulations are liquids, making them easily injectable with a syringe without excessive force.
[0092] The term “space preparation” encompasses any preparation that can be applied to or administered to a mammal or animal body, and does not necessarily have to be administered via a syringe.
[0093] As used in this article, "repeating unit" is the basic repeating unit of a polymer.
[0094] The reaction of methoxy PEG polymers with lactide produces diblock methoxy polyethylene glycol-poly(lactic acid) or mPEG-PLA copolymers. "mPEG" stands for methoxy polyethylene glycol.
[0095] As used herein, polyethylene glycol, abbreviated as PEG throughout the application, is sometimes referred to as poly(ethylene oxide) or poly(ethylene oxide), and these terms are used interchangeably in this invention.
[0096] The abbreviation "PLA" refers to poly(lactic acid). Preferably, polylactic acid is poly(D,L-lactic acid).
[0097] The abbreviation "T" or "TB" refers to triblock copolymers, while the abbreviation "D" or "DB" refers to diblock copolymers.
[0098] The term "triblock" refers, for example, to polyester-PEG-polyester copolymer, and in this invention, to poly(lactic acid)-PEG-poly(lactic acid) copolymer, also known as PLA-PEG-PLA triblock copolymer.
[0099] As used in this article, the term "synovial tissue" refers to the thin, loose vascular connective tissue that makes up (more specifically, lines the interior of all joints and the sheaths surrounding tendons in things like the hands and feet). Synovial tissue contains two types of synovial cells: one type secretes a viscous fluid called synovial fluid (containing proteins and hyaluronic acid) and acts as a lubricant and nutrient for the surface of articular cartilage; the second type acts as phagocytes and clears debris, blood, or foreign objects from within the knee joint.
[0100] As used in this article, "synovium" is the membrane surrounding a joint, also known as synovial tissue, which secretes a fluid that lubricates and nourishes the tissue.
[0101] As used in this article, "other joint tissues" include, but are not limited to, articular cartilage, ligaments, menisci, tendons, rotator cuff, etc.
[0102] As used in this article, "intra-articular" refers to the space within a joint between two bones, specifically the joint portion contained within the joint capsule. It means "inside the joint," and can refer to the space itself, or, in the case of a moving joint, any tissue or fluid found within it. Within the intra-articular space are synovial fluid (the lubricating fluid of the joint) and articular cartilage, which provides a virtually frictionless sliding surface or cushioning pad between adjacent bone surfaces. Other joint types may be characterized by ligaments connecting the two bones within their intra-articular space. In synovial or moving joints, these tissues are located outside the joint or outside the joint capsule.
[0103] As used herein, “targeting” refers to a method of delivering at least one pharmaceutically active ingredient to a mammal or animal in a way that increases the concentration of the drug in the synovial tissue relative to other parts of the body. This targeting allows for the prolongation and localization of the pharmaceutically active ingredient in the synovial tissue.
[0104] "Fragmentation" refers to the action of breaking down into fragments or particles, subdividing, or dispersing. It is the same as pulverizing. Fragmentation can be used non-surgically through intra-articular injection to target joints and joint cells, cartilage, ligaments, tendons, synovial fluid, rotator cuff, meniscus, or inflammatory diseases (such as osteoarthritis, rheumatoid arthritis) or joint pain.
[0105] Therefore, in one aspect, the present invention relates to a method for treating or managing pain or inflammation in a patient following total knee arthroplasty (TKR), the method comprising administering a biodegradable drug delivery composition to the patient's knee joint, the composition comprising:
[0106] (a) Biodegradable triblock copolymers having the following formula:
[0107] PLA v -PEG w -PLA x
[0108] In the formula, v and x are the number of repeating units ranging from 24 to 682, w is the number of repeating units ranging from 4 to 273, and v = x or v ≠ x;
[0109] (b) Biodegradable diblock copolymers having the following formula:
[0110] mPEG y -PLA z
[0111] In the formula, y and z are the number of repeating units, with y ranging from 3 to 68 and z ranging from 7 to 327.
[0112] In the biodegradable pharmaceutical composition, the ratio of the biodegradable triblock copolymer in (a) to the biodegradable diblock copolymer in (b) is from 3:2 to 1:19; and
[0113] (c) Nonsteroidal anti-inflammatory drugs (NSAIDs).
[0114] Treatment or management of pain includes the complete elimination of pain caused by TKR, or the reduction of pain, such as decreasing the intensity and / or shortening the duration of pain. The methods of the present invention also treat or manage inflammation of the knee joint, i.e., they reduce or eliminate inflammation caused by TKR.
[0115] Pain can be current pain, that is, pain felt at the time the patient reports it. Alternatively, pain can be recalled pain, which is the most severe pain the patient has felt in the past 12 hours.
[0116] Preferably, the patient has not previously received TKR, i.e., the present invention relates to a method for treating or managing pain or inflammation in a patient receiving TKR for the first time using a biodegradable drug delivery composition.
[0117] Three patient groups are described. These groups are:
[0118] i) Patients who have never had any knee replacement (described in this application as patients who have never had a TKR, or who have never had a TKR, or who have no TKR);
[0119] ii) Patients who have undergone TKR in one leg but require revision TKR due to certain complications (who did not participate in the clinical studies described in this application);
[0120] iii) Patients who previously received TKR in one leg and then received a second TKR in the contralateral leg (referred to as patients who previously received TKR in our data).
[0121] Therefore, in this invention, the treatment leg has not previously received TKR. Most preferably, both legs have not previously received TKR, hereinafter referred to as the patient having not previously received TKR.
[0122] In another aspect, the present invention provides a method for treating or managing pain or inflammation in a patient after TKR, the method comprising administering a biodegradable drug delivery composition to the patient's knee joint, the composition comprising:
[0123] (a) Biodegradable triblock copolymers having the following formula:
[0124] PLA v -PEG w -PLA x
[0125] In the formula, v and x are the number of repeating units ranging from 24 to 682, w is the number of repeating units ranging from 4 to 273, and v = x or v ≠ x;
[0126] (b) Biodegradable diblock copolymers having the following formula:
[0127] mPEG y -PLA z
[0128] In the formula, y and z are the number of repeating units, with y ranging from 3 to 68 and z ranging from 7 to 327.
[0129] In the biodegradable pharmaceutical composition, the ratio of the biodegradable triblock copolymer in (a) to the biodegradable diblock copolymer in (b) is from 3:2 to 1:19; and
[0130] (c) Nonsteroidal anti-inflammatory drugs (NSAIDs)
[0131] The patient had not previously received TKR.
[0132] When applied to a joint, the biodegradable drug delivery composition may be subjected to mechanical forces through the joint's internal structure, joint movement, weight-bearing, and / or synovial fluid pressure. This mechanical action is believed to contribute to the fragmentation of the biodegradable drug composition. During this fragmentation process, the biodegradable drug delivery composition is broken down into fragments. These fragments are taken up by the synovial tissue and may further degrade into increasingly smaller fragments over time. These smaller fragments can range from 1 cm to 1 mm, and further to 1 micrometer.
[0133] In the biodegradable drug delivery composition, a nonsteroidal anti-inflammatory drug (NSAID) may be present in an amount of 1% to 85% (w% / w%), 1% to 60% (wt% / wt%), 10% to 60% (wt% / wt%), 10% to 30% (wt% / wt%), 10% to 20% (wt% / wt%), or about 15% (wt% / wt%) of the total composition. In another embodiment, the NSAID may be present in an amount of 1% to 40% (w% / w%) in the biodegradable drug composition. In another embodiment, the NSAID may be present in an amount of 5% to 40% (w% / w%) in the biodegradable drug delivery composition. In another embodiment, the NSAID may be present in an amount of 5% to 15% (w% / w%) in the biodegradable drug delivery composition. In yet another embodiment, the NSAID may be present in an amount of 5% to 30% (w% / w%) in the biodegradable drug delivery composition.
[0134] Biodegradable drug delivery compositions may also contain antioxidants such as alkyl gallate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), α-tocopherol, ascorbic acid, polyphenols, flavonoids, beta-carotene, vitamin A, vitamin C, vitamin E, lipoic acid, dithiacyclopententhione, lecithin, glutathione, selenium, quercetin, melatonin, sodium sulfite, sodium bisulfite, sodium metabisulfite, thioglycolic acid, monothioglycerol, L-cysteine, or combinations thereof.
[0135] Possible NSAID compounds include non-COX-2 specific or COX-2 specific drugs, such as COX-2 inhibitors, mPEGS-1 inhibitors, EP4 receptor antagonists, etofenadine, celecoxib, alprazosib, rofecoxib, nabumetone, benorilate, etoricoxib, ampicillin, aminopyrine, vardicoxib, acetaminophen, buphenoxylate, nimesulide, parecoxib, mefenamic acid, dextrobuprofen, etc. Ibuprofen, flurbiprofen, aspirin, dextrokeprofen, diclofenac, diflunisal, etodoxacin, fenofoscillamide, fenofoscillamide, indomethacin, ketoprofen, ketoroxyprofen, lornoxicam, loxoprofen, Loxomac, romecoxib, meclofenamic acid, meloxicam, naproxen, Naprosyn, nimaloxos, oxapazine, piroxicam, disalicylate, sulindac, tenoxicam, tofenamic acid, and mixtures thereof.
[0136] The NSAID can be at least one of the following: etofenadine, celecoxib, alpracoxib, rofecoxib, nabumetone, benorilate, etoricoxib, ampicillin, aminopyrine, vardicoxib, acetaminophen, buprofen, nimesulide, parecoxib, mefenamic acid, dextro ibuprofen, ibuprofen, flurbiprofen, aspirin, dexketoprofen, diclofenac, diflunisal, etoricoxib, fenofosoxib, indomethacin, ketoprofen, ketorolac, lornoxicam, loxoprofen, Loxomac, romecoxib, meclofenamic acid, naproxen, Naprosyn, nimaloxos, oxaprazin, piroxicam, disalicylate, sulindac, tenoxicam, tofenamic acid, and ropivacaine. Preferably, the NSAID is a COX-2 inhibitor; more preferably, the NSAID is celecoxib. A mixture of NSAIDs described herein may also be administered. The choice of mixture depends on the patient's symptoms.
[0137] The drug delivery composition may also include local anesthetics such as bupivacaine, mepivacaine, articaine, ropivacaine, debucaine, eticaine, tetracaine, lidocaine, celecoxine, etc., including mixtures and / or salts and / or derivatives thereof.
[0138] In one embodiment, the composition comprises celecoxib in an amount of 13% to 17% (wt% / wt%) of the total composition, a triblock copolymer in an amount of 7% to 9% (wt% / wt%) of the total composition, a diblock copolymer in an amount of 30% to 34% (wt% / wt%) of the total composition, and dimethyl sulfoxide in an amount of 43% to 47% (wt% / wt%) of the total composition.
[0139] Typically, the composition is administered to the patient in volumes of 0.1 to 6 mL, or 2 to 5 mL, or 3 to 4 mL. Typically, the celecoxib concentration of the composition is from about 150 mg / mL to about 200 mg / mL, or from about 170 to about 190 mg / mL.
[0140] In one embodiment, about 625 mg of celecoxib is administered to the patient. In a preferred embodiment, the composition is administered to the patient in a volume of about 3.5 mL.
[0141] Typically, after a single administration of the celecoxib-containing composition according to the invention, the maximum plasma concentration of celecoxib reached 24 hours after TKR is less than 200 ng / mL, optionally less than 180 ng / mL, and optionally less than 160 ng / mL.
[0142] Typically, the release of therapeutically effective concentrations of NSAID lasts for at least 4 weeks, preferably at least 6 weeks.
[0143] In the method of the present invention as described herein, the molecular weight of the polyethylene glycol chains in the triblock and diblock copolymers can be from 300 kDa to 12 kDa. In another aspect, the molecular weight of the polyethylene glycol chains in the triblock and diblock copolymers can be from 5 kDa to 8 kDa. In yet another aspect, the molecular weight of the polyethylene glycol chains in the triblock and diblock copolymers can be from 1 kDa to 5 kDa. In yet another aspect, the molecular weight of the polyethylene glycol chains in the triblock and diblock copolymers can be from 1 kDa to 2 kDa. In yet another aspect, the molecular weight of the polyethylene glycol chains in the triblock copolymers is 2 kDa, and the molecular weight of the polyethylene glycol chains in the diblock copolymers is 1 kDa. In yet another aspect, the molecular weight of the polyethylene glycol chains in the triblock copolymers is 1 kDa, and the molecular weight of the polyethylene glycol chains in the diblock copolymers is 2 kDa. In one embodiment, the molecular weight of the polyethylene glycol chains in the triblock copolymers and / or diblock copolymers is from 1.5 to 2.5 kDa.
[0144] In another aspect, the molecular weight of the polyethylene glycol chain in the triblock is about 2 kDa, and the molecular weight of the polyethylene glycol chain in the diblock is about 2 kDa.
[0145] The molecular weight mentioned above can be either number-average molecular weight (Mn) or weight-average molecular weight (Mw), but it is usually number-average. Number-average molecular weight (Mn) and weight-average molecular weight are typically measured by gel permeation chromatography (GPC), usually using polystyrene standards. The polydispersity index is defined as the ratio of Mw to Mn, and is typically greater than 1 and less than 2.
[0146] Alternatively, or as an alternative to defining polymers based on number-average molecular weight, polymers can be defined based on their theoretical molecular weight. The term "theoretical molecular weight" refers to the molecular weight of a copolymer determined by calculating the total molar mass of the repeating units constituting the polymer. The theoretical molecular weight indicates the average length of the target polymer chain.
[0147] In the method of the present invention as described herein, the molar ratio of lactic acid to ethylene oxide in the triblock copolymer may be 1.6 to 7.2, or 1.6 to 5.0, or 1.6 to 3.0, or about 2.0.
[0148] In the method of the present invention as described herein, the molar ratio of lactic acid to ethylene oxide in the diblock copolymer may be 1.6 to 7.2, or 1.6 to 5.0, or 1.9 to 4.8, or 1.9 to 3.0, or about 2.4.
[0149] In one embodiment, the molar ratio of lactic acid to ethylene oxide in the triblock copolymer is 1.6 to 7.2, and the molar ratio of lactic acid to ethylene oxide in the diblock copolymer is 1.9 to 4.8.
[0150] In another embodiment, the molar ratio of lactic acid to ethylene oxide in the triblock copolymer can be from 2.0 to 6.0, and the molar ratio of lactic acid to ethylene oxide in the diblock copolymer can be from 2.0 to 3.0. In yet another aspect, the molar ratio of lactic acid to ethylene oxide in the triblock copolymer can be from 3.0 to 6.5, and the molar ratio of lactic acid to ethylene oxide in the diblock copolymer can be from 2.5 to 4.5.
[0151] The molar ratio of lactic acid to ethylene oxide is usually determined by... 1 H-NMR determination.
[0152] The degree of polymerization is the total number of repeating units in ethylene oxide and lactic acid; that is, the degree of polymerization of a triblock copolymer is v+w+x, or the degree of polymerization of a diblock copolymer is y+z.
[0153] Typically, the degree of polymerization in triblock copolymers is 92 to 135, and in diblock copolymers it is 91 to 180; or the degree of polymerization in triblock copolymers is 95 to 130, and in diblock copolymers it is 95 to 175; or the degree of polymerization in triblock copolymers is 99 to 132, and in diblock copolymers it is 95 to 175; or the degree of polymerization in triblock copolymers is 100 to 170, and in diblock copolymers it is 115 to 195.
[0154] In one embodiment, the triblock copolymer is present in an amount of 2% to 45% (wt% / wt%), or 6% to 24% (wt% / wt%), or 6% to 15% (wt% / wt%), 6% to 10% (wt% / wt%), or about 8% (wt% / wt%) of the total composition.
[0155] In one embodiment, the diblock copolymer is present in an amount of 8% to 50% (wt% / wt%), or 12% to 40% (wt% / wt%), or 20% to 40% (wt% / wt%), or about 32% (wt% / wt%) of the total composition.
[0156] In one embodiment, the triblock copolymer is present in an amount of 6% to 24% (wt% / wt%) of the total composition, and the diblock copolymer is present in an amount of 12% to 40% (wt% / wt%) of the total composition. Typically, the total polymer content is 20% to 50% (w% / w%), or 30% to 50% (w% / w%), or about 40% (w% / w%) of the total composition.
[0157] In one embodiment, the triblock may be present in the biodegradable pharmaceutical composition at an amount of 5% to 30% (wt% / wt%), and the diblock may be present at an amount of 15% to 25% (wt% / wt%). In another embodiment, the triblock may be present in the biodegradable pharmaceutical composition at an amount of 10% to 40% (wt% / wt%), and the diblock may be present at an amount of 10% to 20% (wt% / wt%). In yet another embodiment, the triblock may be present in the biodegradable pharmaceutical composition at an amount of 15% to 50% (wt% / wt%), and the diblock may be present at an amount of 5% to 35% (wt% / wt%).
[0158] In one embodiment, the total polymer content is 30% to 50% (w% / w%) of the total composition, and the NSAID is present in an amount of 10% to 20% (w% / w%) of the total composition.
[0159] Preferably, the composition further comprises a pharmaceutically acceptable carrier. Typically, a pharmaceutically acceptable carrier is a biocompatible organic solvent. Biocompatible organic solvents may be selected from: benzyl alcohol, benzyl benzoate, dimethyl isosorbide (DMI), dimethyl sulfoxide (DMSO), ethyl acetate, ethyl benzoate, ethyl lactate, glycerol formaldehyde, methyl ethyl ketone, methyl isobutyl ketone, N-ethyl-2-pyrrolidone, N-methyl-2-pyrrolidone (NMP), pyrrolidone-2, tetraethylene glycol, triacetin, glyceryl tributyrate, tripropionate (tripro), and mixtures thereof. In one embodiment, the solvent is DMSO, tripro, NMP, and mixtures thereof, preferably DMSO.
[0160] In the method of the present invention as described herein, the preparation of the biodegradable pharmaceutical composition comprises: mixing a triblock copolymer and a diblock copolymer in a biocompatible organic solvent to form a mixture of the triblock copolymer and the diblock copolymer. Then, NSAID is added to the mixture of the triblock copolymer and the diblock copolymer. The solvent may be removed by evaporation.
[0161] There are no particular restrictions on the type of total knee replacement (TKR) performed. For example, any known total knee replacement implant, partial knee replacement implant, or knee replacement surgical method can be used. The surgery is usually performed under general or spinal anesthesia. Intravenous sedation, such as propofol or midazolam, is typically administered perioperatively.
[0162] Biodegradable drug delivery compositions are typically administered via syringe into the intra-articular space at the end of a TKR procedure, just before the wound is to close. Generally, as much synovial fluid as possible should be aspirated before administration. The compositions of this invention are typically administered at the level of the lateral femoral condyle into the lateral recess of the knee joint. The formulation is administered only after any knee flexion (e.g., during implant fitting or alignment testing) and just before closure to prevent undesirable discharge and loss of the compositions of this invention via arthroplasty.
[0163] Typically, the method of the present invention also includes the administration of standardized multimodal analgesia (MMA).
[0164] The limitations of opioid analgesia and a deeper understanding of pain physiology have led to the development of alternative pain management approaches, collectively known as multimodal analgesia. First introduced by Kehlet and Dahl in 1993, the primary goal of multimodal analgesia is to reduce opioid dependence, thereby minimizing opioid-related side effects. Multimodal analgesia involves a combination of analgesics from more than one pharmacological class, targeting different receptors in the pain pathway, with the aim of improving analgesia while reducing the side effects associated with individual classes.
[0165] Multimodal analgesia (MMA) is currently the standard of care for pain management after total kinesthetic resection (TKR), and it involves selecting analgesics that target different but complementary sites of action. This typically includes opioids, acetaminophen, periarticular injections, peripheral nerve blocks, pregabalin for neuropathic pain, and anti-inflammatory drugs.
[0166] Current evidence supports the routine use of multimodal analgesia in the perioperative period to eliminate over-reliance on opioids for pain control and reduce opioid-related adverse events.
[0167] The specific combination of drugs and their dosages that constitute multimodal analgesia will depend on the surgeon's experience and the patient's medical history.
[0168] The methods of this invention generally involve the simultaneous administration of standardized multimodal analgesia. The timing of administration of each drug constituting multimodal analgesia will depend on the specific drug and its purpose, as well as the needs of the particular patient. Therefore, standardized multimodal analgesia can be administered before, during, and / or after TKR (transmitted keratolysis). Compared to administering standardized multimodal analgesia alone, the methods of this invention provide improvements in the treatment or management of pain or inflammation.
[0169] Standardized multimodal analgesia may comprise two or more active pharmaceutical ingredients selected from the following: bupivacaine, ropivacaine, lidocaine, acetaminophen, mesobamoline, pregabalin, gabapentin, ketamine, morphine, oxycodone, hydrocodone, hydromorphone, fentanyl, tramadol, tapentadol, nerve blockers, and dexamethasone. In one embodiment, standardized multimodal analgesia comprises bupivacaine hydrochloride, acetaminophen, and mesobamoline.
[0170] It should be noted that mesopamo is a muscle relaxant used to treat muscles in the back or legs, and therefore it is not strictly speaking an analgesic for the knee joint. Therefore, in some implementations, mesopamo is not included in the aforementioned list of multimodal analgesics and can be administered in addition to standardized multimodal analgesia.
[0171] Nerve blockers can be administered by injection or through an indwelling catheter. They can be applied to the femoral nerve or adductor canal.
[0172] Neuropathic pain can be treated with gabapentin-type drugs such as pregabalin or gabapentin.
[0173] Bupivacaine, ropivacaine, or lidocaine can be administered via periarticular infiltration, typically by injection into the soft tissues of the knee joint.
[0174] Opioids (such as morphine, oxycodone, hydrocodone, hydromorphone, fentanyl, tramadol, tapentadol, or combinations thereof) can be administered orally or intravenously to treat severe pain.
[0175] In addition to the NSAID administered in a biodegradable drug delivery composition, in one embodiment, one or more other NSAIDs may be administered alone as part of multimodal analgesia. The one or more other NSAIDs may be selected from celecoxib, meloxicam, diclofenac, ibuprofen, naproxen, or combinations thereof.
[0176] In one implementation, bupivacaine is administered via periarticular infiltration. For subjects weighing less than 80 kg, a mixture of 0.25% bupivacaine with epinephrine (1:200,000) and 0.25% bupivacaine without epinephrine is used at a ratio of 2:1. For subjects weighing more than 80 kg, a mixture of 0.25% bupivacaine with epinephrine (1:200,000) and 0.25% bupivacaine without epinephrine is used at a ratio of 3:1, administered at a maximum of 90 mL / kg. Bupivacaine is typically administered during the procedure. Bupivacaine is a local anesthetic. After TKR, oral acetaminophen is administered, followed by mesopamool if necessary. Acetaminophen is an analgesic, and mesopamool is a muscle relaxant. Acetaminophen is administered orally, usually 650 mg every 8 hours (up to 1950 mg / day), for up to 6 weeks after TKR. Mesobamor is usually administered at a dose of 750 mg every 8 hours.
[0177] Standardized multimodal analgesia typically includes opioids. Opioids can be administered orally or intravenously. Opioids can be selected from, but are not limited to, morphine, oxycodone, hydrocodone, hydromorphone, fentanyl, tramadol, tapentadol, and combinations thereof. In one embodiment, the opioid is morphine and / or oxycodone. Each opioid dosing regimen will be prescribed based on the surgeon's, patient's needs, and tolerability (e.g., 10 mg of immediate-release oxycodone orally every 4 hours, up to a maximum of 60 mg / day). One advantage of this invention is the reduction in opioid consumption, thereby lowering the risk of opioid addiction.
[0178] In one implementation, the average cumulative opioid consumption of the patient is reduced compared to patients who receive only standardized multimodal analgesia containing opioids; optionally, the reduction occurs 2 weeks to 90 days after TKR, or within 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, or 90 days after TKR.
[0179] In one implementation, when analyzing all patients, cumulative opioid consumption was reduced by 15% to 20% 90 days after TKR. In another implementation, for patients who had not previously received TKR, cumulative opioid consumption was reduced by 25% to 30% 90 days after TKR.
[0180] In one implementation, the patient’s daily opioid consumption is reduced compared to a patient receiving only standardized multimodal analgesia containing opioids; optionally, the daily opioid consumption is reduced from 2 weeks to 90 days after TKR, or within 2 weeks, 4 weeks, 6 weeks, 12 weeks, or 90 days after TKR.
[0181] Daily opioid consumption or average cumulative opioid consumption is typically measured in morphine milliequivalents (MME).
[0182] Daily opioid consumption, measured in oral morphine milligram equivalents (MME), is determined by calculating the total daily dose of opioids (dose × daily frequency) and converting it to an equivalent amount of oral morphine sulfate using a conversion factor (referred to as the morphine equivalent daily dose (MED)).
[0183] The cumulative opioid consumption in milligram equivalents (MME) over a period of time is determined by calculating the total daily dose of opioids (dose × daily frequency), converting it to an equivalent amount of oral morphine sulfate (called the morphine equivalent daily dose (MED)) using a conversion factor, and then summing it up cumulatively over that period of time (e.g., 90 days).
[0184] In one implementation, the area under the curve (AUC) of the numerical rating scale (NRS) pain score is reduced at 3, 7, 2, 6, or 90 days after TKR, compared to patients receiving only standardized multimodal analgesia. Optionally, the reduction is calculated based on the least-squares mean of the NRS AUC. In one implementation, the least-squares mean of the NRS pain score AUC can be reduced by at least 3%, optionally at least 4%, optionally at least 5%, and optionally at least 6%, compared to patients receiving only standardized multimodal analgesia. In patients who have not previously received TKR, the least-squares mean of the NRS pain score AUC can be reduced by at least 8%, optionally at least 9%, optionally at least 10%, optionally at least 12%, optionally at least 14%, and optionally at least 16%, compared to patients receiving only standardized multimodal analgesia.
[0185] In one implementation, the AUC of the Numerical Rating Scale (NRS) pain score was statistically adjusted or imputed based on opioid consumption. Statistical adjustment was performed using windowed worst-of-observations carryover (wWOCF) imputed (NK Singla et al., Pain Ther. December 2017; 6(2): 165–175, “Exploring the Interplay between Rescue Drugs, Data Imputation, and Study Outcomes: Conceptual Review and Qualitative Analysis of an Acute Pain Data Set”. This method is used to prevent the NRS pain scores recorded by patients from being artificially suppressed due to the therapeutic effects of opioids. In this method, NRS scores collected within the therapeutic window of the consumed opioid (e.g., 4 hours for oxycodone) are replaced with NRS scores collected immediately before the opioid is consumed.
[0186] Postoperative pain intensity was recorded using a Numerical Rating Scale (NRS-11). The NRS consists of an 11-point segmented numerical scale ranging from 0 to 10, where 0 represents no pain and 10 represents the most severe imaginable pain. Patients were asked to select the corresponding number to indicate the intensity of pain they were experiencing. The scale can be administered verbally or graphically. The AUC of the numerical rating is the area under the curve of the NRS over time.
[0187] Pain can also be assessed using the Continuous Visual Analogue Scale (VAS), which consists of a 10 cm horizontal line anchored at both ends by two verbal descriptors: "no pain" (score 0) and "pain as severe as possible" or "the most severe pain imaginable" (score 10). Patients are asked to report the maximum pain intensity "in the past 24 hours." The VAS scale is displayed as a 10 cm line and measured with a ruler. The least squares mean of the VAS values can be determined.
[0188] In another implementation, the least squares mean of the visual analog scale for pain is reduced at 2 weeks, 6 weeks, or 90 days after TKR, relative to patients who only receive standardized multimodal analgesia; optionally, the reduction is at least 10% difference in the least squares mean of the VAS, optionally at least 20% difference.
[0189] In one implementation, compared to patients who only receive standardized multimodal analgesia, the time it takes for patients to achieve a range of motion of 100 to 110 degrees of knee joint is shortened.
[0190] In another implementation, the patient’s range of motion (ROM) improved 1 week to 3 months after TKR compared to the patient receiving only standardized multimodal analgesia; or improved ROM at 1 week, 2 weeks, 3 weeks, 6 weeks, or 12 weeks after TKR; optionally, at 3 months after TKR, ROM improved by 5% to 10% compared to the patient receiving only standardized multimodal analgesia.
[0191] With the subject supine, a goniometer was used to measure the passive range of motion (ROM) of the knee joint during flexion and extension to prevent interference from rectus femoris muscle tension. The fixed arm of the goniometer was positioned between the greater trochanter of the femur and the mid-femur, while the movable arm was positioned along a straight line from the fibular head to the lateral malleolus of the ankle. To minimize measurement error, the average of three repeated measurements was recorded.
[0192] In one implementation, the patient's knee joint effusion is reduced, and the knee joint effusion is measured as a percentage difference in circumference between the knee that has undergone TKR and the contralateral knee, as well as between the knee that has undergone TKR and a patient who has only received standardized multimodal analgesia; optionally, the measurement is performed 2 weeks, 6 weeks, or 3 months after TKR.
[0193] The measuring tape method is used to measure effusion in the knee joint as an indicator of inflammation. This method uses a standardized, sterile, disposable soft measuring tape to measure the circumference 5 cm above the knee joint line while the subject is supine. Both the affected and contralateral knees should be measured. To minimize measurement error, the average of three repeated measurements is required.
[0194] In another implementation, the patient’s activity level improved as measured by a timed stand-up walking test, which measures the time required for the patient to stand up, walk 3 meters (10 feet), turn around, walk back and sit down again, compared to a patient who only received standardized multimodal analgesia. Optionally, the timed stand-up walking test results were measured 2 weeks, 6 weeks or 3 months after TKR.
[0195] The Timed-Up-and-Go Test (TUG) is a simple, validated test (TS Yeung, J. Wessel, PW Stratford, JC MacDermid, The Timed-Up-and-Go Test for use on an inpatient orthopaedic rehabilitation ward). The Journal of orthopedic and sports physical therapy38(7) (2008) 410-417), used to assess functional mobility in individuals following orthopedic surgery. The test records the time required for a subject to stand up from a chair, walk three meters, turn around, walk back to the chair, and sit down. During the test, subjects are expected to wear their usual shoes and use any mobility aids they normally require. A stopwatch is used to record the time taken to complete the test to the nearest 1 / 100th of a second.
[0196] In one implementation, the composite score of physical function and / or body composition summary score of the Summary Table 12 Health Survey (SF-12v2) is at least 15% or at least 30% higher than the value of patients receiving only standardized multimodal analgesia.
[0197] The Short Form 12 Health Survey (SF-12v2) is a survey that assesses participants' functional status and well-being using 12 questions covering selected concepts, including physical functioning, somatic role functioning, bodily pain, general health, vitality, social functioning, emotional role functioning, and mental health. SF-12v2 data are used to calculate participants' utility values. Results can be aggregated using the Somatic Components Score (PCS) and the Mental Components Score (MCS).
[0198] In yet another embodiment, compared to patients receiving only standardized multimodal analgesia, the patient's health status improved as measured by the EuroQoL 5D (EQ-5D-5L) index at 2 weeks post-TKR; optionally, the index increased by at least 70 or at least 85 compared to patients receiving only standardized multimodal analgesia. In one embodiment of the invention, in patients who had not previously received TKR, the index at 2 weeks post-TKR increased by at least 150 or at least 170 compared to patients receiving only standardized multimodal analgesia.
[0199] The EuroQoL 5D (EQ-5D-5L) is a standardized measure of a subject's health status, utilizing a five-question scale covering selected dimensions and a VAS (Values and Analyses) scale. These dimensions cover mobility, self-care, daily activities, pain / discomfort, and anxiety / depression. Responses to each dimension are recorded at five severity levels (no problem, minor problem, moderate problem, severe problem, and very severe problem). Utility values are based on an individual's responses to the five questions. Higher utility values indicate better health.
[0200] In one implementation, patients who received standardized multimodal analgesia alone showed improvement in their 2011 Knee Society Score (KSS2011) measured 2 weeks after TKR; optionally, their KSS2011 patient satisfaction and / or functional activity scores increased by at least 30%, at least 40%, or at least 50% compared to patients who received standardized multimodal analgesia alone. Patients who had not previously received TKR typically showed an increase in KSS2011 patient satisfaction and / or functional activity scores of at least 40%, at least 50%, or at least 60% compared to patients who received standardized multimodal analgesia alone.
[0201] The Knee Society Knee Scoring System (KSS), updated in 2011, is a validated system that combines objective physician assessments with subjective patient reports to evaluate pain relief, functional capacity, satisfaction, and expectation achievement. The scoring prioritizes the patient's perspective to track expectations, satisfaction, and activity levels.
[0202] In one embodiment, the biodegradable drug delivery composition is drawn into a syringe for administration and injected into the knee joint; or, the formulation is manually formed into a solid mass by exposing it to an aqueous liquid and manually placing it into the knee joint.
[0203] In one embodiment, the biodegradable drug delivery composition is subjected to mechanical forces. Typically, these mechanical forces are generated by the internal structure of the joint, joint movement, weight-bearing, and / or synovial fluid pressure.
[0204] In another aspect, the present invention provides a composition for use in the methods defined above.
[0205] Other pharmaceuticals or bioactive agents that can be released in an aqueous environment will also be used in the described delivery system. Furthermore, various forms of pharmaceuticals or bioactive agents can be used. These include, but are not limited to, uncharged molecules, molecular complexes, salts, ethers, esters, amides, etc., which are bioactivated when injected into an animal, used as a spatial formulation to allow application to an animal or its body, or as a rod-shaped implant.
[0206] The pharmaceutically effective amount of an NSAID or other active ingredient can vary depending on the NSAID or other active ingredient, the degree of pain in the animal, and the time required to deliver the active ingredient. There is no critical upper limit to the amount of active ingredient incorporated into a polymer solution, except for an acceptable solution or dispersion viscosity for injection via a syringe needle and its ability to effectively manage pain without causing overdose in human or animal patients. The lower limit of active ingredient incorporated into a delivery system depends solely on the activity of the active ingredient and the length of time required for treatment.
[0207] Typically, for human treatment, the NSAID is present in the composition at a concentration of about 150 mg / mL to about 200 mg / mL, optionally about 160 mg / mL to about 190 mg / mL, optionally about 170 mg / mL to about 190 mg / mL.
[0208] In the biodegradable drug delivery composition used in this invention, a pharmaceutically effective amount of NSAID can be gradually released over an extended period of time. This slow release can be continuous or discontinuous, linear or non-linear, and can vary depending on the composition of the triblock copolymer and diblock copolymer. Therefore, the higher the lactic acid content of the triblock copolymer and diblock copolymer compared to the polyethylene glycol content, and the greater the amount of triblock copolymer and diblock copolymer present in the biodegradable drug composition, the longer the release of the active ingredient or drug. In other words, the higher the LA / EO molar ratio of the triblock copolymer and diblock copolymer, and the greater the weight percentage of the triblock copolymer and diblock copolymer, the longer the time required for the active ingredient to be released from the drug composition.
[0209] Biodegradable drug delivery compositions can be injectable liquids at room temperature and can be injected with a syringe without excessive force. However, these biodegradable drug delivery compositions are also in-situ formed and biodegradable, and become solid implants or reservoirs upon contact with aqueous liquids after injection into human or animal patients. Alternatively, the biodegradable drug composition can be produced as a solid, prepared into small particles, and used as a powder, sprinkled on the site of injury. In another aspect, the drug delivery composition is a rod-shaped implant that can be implanted subcutaneously or in another compartment of the body. In yet another aspect, the drug delivery composition can be prepared as a film and applied as a film. In yet another aspect, the biodegradable drug delivery composition can be used as a spatial formulation, allowing it to be administered onto or into the body of a human or animal patient.
[0210] Some mPEG-OH is contaminated with a small amount of OH-PEG-OH. By following the method of this invention and using the contaminated mPEG-OH, the final product will be mPEG-PLA contaminated with a small amount of PLA-PEG-PLA, which is covered by this invention.
[0211] Many embodiments and / or aspects of the invention have been described. However, it will be understood that various modifications can be made without departing from the spirit and scope of the invention. Example
[0212] Example 1: Polymer Synthesis
[0213] The copolymer was synthesized with minor modifications according to the method described in U.S. Patent No. 6,350,812 (incorporated herein by reference). Typically, the desired amount of PEG (to obtain a triblock copolymer) or methoxy-PEG (to obtain a diblock copolymer) was heated to 65 °C and vacuum dried in a reactor vessel for 2 hours. D,L-lactide (corresponding to the target lactic acid / ethylene oxide (LA / EO) molar ratio) and zinc lactate (in 1 / 1000 of the amount of lactide) were added. The reaction mixture was first dehydrated by three brief vacuum / N2 cycles. The reaction mixture was heated to 140 °C and rapidly degassed under vacuum. The reaction was carried out at 140 °C for four days under a constant nitrogen flow (0.2 bar). The reaction was cooled to room temperature, its contents were dissolved in acetone, and then precipitated with ethanol. The resulting product was subsequently dried under reduced pressure. Alternatively, the copolymer can be purchased from Corbion.
[0214] The obtained product is obtained through 1 H NMR was used to characterize the residual lactide content and to determine the LA / EO molar ratio. 1 H NMR spectroscopy analysis was performed using a Brucker Advance 300 MHz spectrometer. For all 1 ¹H NMR spectra were obtained, and the characteristic peaks of PLA and PEG were integrated and analyzed using TopSpin software. Chemical shifts were referenced to the solvent value of CDCl₃ at δ = 7.26 ppm.
[0215] The resulting products were further characterized by gel permeation chromatography (GPC) to determine their molecular weight distribution. GPC was performed using an LC system equipped with a differential refractive index detector. This instrument could be equipped with a range of Waters Styragel columns selected from HR4, HR3, HR2, and HR1, which were maintained at a constant temperature. The samples were run at a constant flow rate in BHT-stabilized THF. The molecular weight distribution (Mn; Mw and polydispersity index) was determined by routine calibration using polystyrene calibration standards.
[0216] The triblock polymers described in this paper are designated PxRy, where x represents the PEG chain size in kDa and y is the LA / EO molar ratio. The diblock mPEG-PLA polymers described in this paper are designated dPxRy, where x represents the PEG chain size in kDa and y is the LA / EO molar ratio.
[0217] Example 2: Preparation of a specific formulation for celecoxib
[0218] The formulation described herein is based on an organic solution containing a polymer of celecoxib as a drug. Typically, 0.4 g of the polymer (corresponding to a diblock copolymer and a triblock copolymer mixed in a specified mass ratio) is dissolved overnight at room temperature with constant magnetic stirring in 0.57 g of a biocompatible solvent. This solvent can be a single solvent or a combination of solvents. The next day, 20 mg of celecoxib is added to the polymer solution and stirred until completely dissolved. When the drug is insoluble in the solvent, a suspension of the drug in the polymer solution is obtained. Alternatively, the drug can be dissolved or suspended in a biocompatible solvent, followed by the addition of the polymer.
[0219] The final formulation F14 is listed in Table 1 below. Load these formulations into syringes before use.
[0220] Table 1: Composition of Formulation F14
[0221]
[0222] Example 3
[0223] A phase 2, randomized, single-blind, active-controlled, parallel-group study was conducted to evaluate the safety and activity of a single administration of formulation F14 for postoperative pain management in patients undergoing unilateral total knee arthroplasty.
[0224] Nine patients simultaneously received a single 3.5 mL dose (625 mg celecoxib) of F14 and protocol-specified multimodal analgesia (MMA) and were compared with 11 subjects who received MMA alone. Randomization was stratified based on whether patients had previously undergone contralateral total knee arthroplasty (TKR). Formulation F14 was administered intraoperatively, at the end of surgery, and just before wound closure via syringe into the intra-articular space. Safety was assessed by recording adverse events, vital signs, ECG, physical examination and knee-specific examinations, laboratory blood tests, and standing X-rays of TKR obtained at 3 and 12 months. Postoperative pain was assessed using the Visual Analogue Scale (VAS) and the Western University and McMaster University Osteoarthritis Index (WOMAC) (Part A) questionnaire. Stiffness and function were assessed using the WOMAC (Parts B and C) questionnaire and the timed stand-up walking test. Concomitant and rescue medications (including morphine milligram equivalents) were recorded in the hospital and then monitored daily via patient medication diaries for up to 3 months, with monitoring again at the 12-month visit. Perceived analgesic benefit was compared using the Overall Analgesic Benefit Score (OBAS). The pharmacokinetic characteristics of celecoxib in plasma were assessed at 3 months and again at 12 months. Patients were screened within 30 days prior to the TKR procedure. Patients were only randomized to the study intervention after the investigator deemed the TKR procedure successful. After the TKR, participants remained in the hospital for at least 24 hours (or longer if indicated). Standardized physical therapy was administered postoperatively. Follow-up study visits were conducted at 1, 2, 3, 4 weeks (by telephone), and 6 weeks, as well as at 3 and 12 months.
[0225] Purpose
[0226] The primary objective of this study was to evaluate the safety of administering F14 during a single surgical procedure in conjunction with standard of care analgesia in participants undergoing unilateral total knee arthroplasty.
[0227] A secondary objective was to investigate the effectiveness of intraoperative administration of F14 in combination with standard of care analgesia to improve postoperative pain and function in participants undergoing unilateral total knee arthroplasty, compared to standard of care alone.
[0228] Another objective of this study was to investigate the effect of intraoperative administration of F14 in combination with standard of care analgesia on reducing opioid use and overall analgesia benefits in participants undergoing unilateral total knee arthroplasty, compared with standard of care alone.
[0229] In addition, the study determined the pharmacokinetic characteristics of celecoxib in plasma after a single intraoperative administration of F14 in participants who underwent unilateral total knee arthroplasty.
[0230] Concomitant medication
[0231] Pain management in the post-anesthesia recovery unit (PACU) is limited to fentanyl (if necessary).
[0232] All participants were administered the following treatment during their postoperative hospital stay and until discharge:
[0233] • Oral acetaminophen - 1000 mg every 8 hours
[0234] Mesobamor (muscle relaxant) - 750 mg every 8 hours if necessary.
[0235] • Non-aspirin-based DVT prophylaxis drugs (e.g., fondaparinux sodium, rivaroxaban, apixaban, enoxaparin)
[0236] In addition, the following anesthetics may be administered as needed, depending on the participants' tolerance and needs:
[0237] • Oral oxycodone - 5-10 mg every 4 hours if necessary
[0238] • Morphine ER - 15 mg every 12 hours if necessary (for participants under 70 years of age)
[0239] For breakthrough pain: Intravenous hydromorphone - 0.2 mg / mL
[0240] For participants with poor tolerance to opioids:
[0241] • Oral hydromorphone - 2-4 mg every 4 hours if necessary
[0242] • Oral hydrocodone - if necessary, 5 / 325 mg (1-2 tablets) every 4 hours.
[0243] • He sprays him more - 50-100 mg every 4 hours if necessary.
[0244] Tramadol - 50-100 mg every 4 hours if necessary.
[0245] Adjust the drug dosage and administration frequency as needed.
[0246] After discharge, participants under 70 years of age were prescribed pregabalin (75 mg, twice daily). In addition to the aforementioned remedial medication, participants may take acetaminophen for analgesia, up to 3000 mg / day. Anti-inflammatory drugs other than meloxicam (including low-dose aspirin and cannabidiol as cardiac prophylaxis) were not permitted for 3 months following the intervention.
[0247] The date and time of all medications taken by each participant after discharge were recorded daily in a medication diary until the 3-month follow-up visit.
[0248] Opioids
[0249] Upon discharge, participants were prescribed opioid medication based on their in-hospital tolerability.
[0250] • Oral oxycodone - 5-10 mg every 4 hours if necessary.
[0251] • Morphine ER - 15 mg, twice daily (for participants under 70 years of age)
[0252] For participants with poor tolerance:
[0253] • Oral hydromorphone - 2-4 mg every 4 hours if necessary
[0254] • Oral hydrocodone - if necessary, every 4 hours, 5 / 325 mg, 1-2 tablets
[0255] • He sprays him more - 50-100 mg every 4 hours if necessary.
[0256] Tramadol - 50-100 mg every 4 hours if necessary.
[0257] Patients may request an NSAID prescription only if the anesthetic is insufficient to manage postoperative pain:
[0258] Meloxicam - 7.5 mg twice daily, or 15 mg once daily.
[0259] The dates and times patients took opioids were recorded daily in their medication diaries for three months. Furthermore, the total dosage was determined by subtracting the number of remaining pills at each follow-up appointment from the total number of each type of pill prescribed at discharge and during follow-up.
[0260] Patients who took opioids during the study were followed up until the end of the study to assess safety and efficacy.
[0261] result
[0262] This phase 2 study found that F14, administered concurrently with MMA, was well-tolerated. The safety profile of the MMA+F14 group was comparable to that of the control group receiving MMA alone. Despite the small study size, F14 demonstrated clinically meaningful efficacy in reducing VAS pain scores compared to MMA at 2 weeks and 3 months post-surgery (see [link to study report]). Figure 2 Compared with the VAS score at 24 hours post-surgery, subjects who received F14+MMA showed a VAS score decrease of more than 50% within 9 days, while subjects who received MMA only (control group) showed a decrease only at 4 weeks.
[0263] Related functional improvements were also observed in the MMA+F14 group at 1 and 2 weeks. Side-by-side analysis showed that, in the absence of other factors influencing subject consumption, F14+MMA significantly demonstrated an opioid-saving effect compared to MMA alone. The consistent and coherent trend in the observed multiple manifestations of postoperative pain and related endpoints in this study supports the efficacy. Even with a limited sample size, it would be unlikely by chance to observe a coherent trend in the multiple manifestations of efficacy.
[0264] The most significant efficacy findings after F14 treatment, compared to MMA alone, are as follows:
[0265] - Daily knee pain scores decreased by up to 47.2% within 90 days post-surgery, characterized by a faster and more consistent decline in VAS scores. Figure 2 )
[0266] - Knee range of motion improved at every time point during the 12-month follow-up period (see plot of knee range of motion in degrees over time during the first 6 weeks). Figure 3 )
[0267] Participants receiving F14 treatment showed faster functional improvement in the timed stand-up walking test. Specifically, at week 1, participants in the F14 group completed the test on average 34.3% faster than those in the control group.
[0268] - Celecoxib's sustained release time is at least 6 weeks, as shown in pharmacokinetic analysis. Figure 1 As shown in the figure
[0269] Figure 1 The changes in plasma celecoxib concentration over time are shown. The maximum plasma celecoxib concentration was 155.3 ng / mL 24 hours after TKR. Due to the acute dosing regimen and local route of administration, it should be understood that the method of this invention will largely avoid systemic adverse events associated with oral celecoxib. In the phase 2 study, the maximum plasma celecoxib concentration 24 hours after TKR (155.3 ng / mL) was only 15% of the concentration (1042 ng / mL) achieved when following general oral celecoxib dosing recommendations (dose range of 200-400 mg daily, chronic dose).
[0270] A single oral dose of 400 mg of celecoxib produces C max The concentration was 1433 ng / mL, almost exactly twice the 705 ng / mL produced by Celebrex® 200 mg. Since a single dose of F14 is equivalent to 625 mg of celecoxib, but results in C... maxWith a concentration of only 155.3 ng / mL, this demonstrates that its systemic load is extremely low compared to commercially available oral formulations.
[0271] Compared to known oral PK of celecoxib, the systemic PK characteristics of celecoxib showed very low exposure even 6 weeks after treatment, providing strong evidence for a sustained intra-articular drug delivery mechanism.
[0272] In Phase 2, the TKR status subgroup was analyzed, in which 7 / 20 (35%) of the subjects had previously received TKR (the remaining subjects had not previously received TKR), but due to the small sample size, no statistical impact on the efficacy was found.
[0273] Example 4: Pain Management After TKR
[0274] Phase 3 trial
[0275] 151 eligible participants were randomly assigned (1:1) to two treatment groups: one group received only the protocol-specified multimodal analgesia (MMA), and the other group received MMA along with a single dose of F14. Of these, 108 participants had no prior history of transarterial keratectomy (TKR); of these, 51 received F14 and 57 received MMA. All participants underwent their initial unilateral, cemented TKR under high-pressure bupivacaine spinal anesthesia. Following TKR implantation, all participants received the same multimodal analgesia (MMA), defined as:
[0276] During the operation:
[0277] • Infiltrate around the joint at a ratio of 1 mL / kg (up to 90 mL). For subjects weighing less than 80 kg, use a mixture of 0.25% bupivacaine with epinephrine (1:200,000) and 0.25% bupivacaine without epinephrine at a ratio of 2:1. For subjects weighing more than 80 kg, use a mixture of 0.25% bupivacaine with epinephrine (1:200,000) and 0.25% bupivacaine without epinephrine at a ratio of 3:1.
[0278] Post-surgery, during hospitalization:
[0279] • Oral acetaminophen - 650 mg every 8 hours (up to 1950 mg / day)
[0280] Mesobamor (muscle relaxant) - 750 mg every 8 hours if necessary.
[0281] Opioid remedial medication
[0282] Post-surgery, after discharge:
[0283] • Oral acetaminophen - 650 mg every 8 hours (up to 1950 mg / day) for 6 weeks
[0284] Opioid remedial medication
[0285] In addition to the MMA mentioned above, the F14 group of 76 subjects received a single 3.5 mL dose (625 mg celecoxib) of F14 via syringe into the intra-articular (IA) space at the end of the TKR procedure, just before the wound closed.
[0286] Upon discharge, the subjects received a 14-day supply of acetaminophen and opioid rescue medication.
[0287] Evaluate
[0288] Postoperative pain intensity was recorded using a numerical rating scale (NRS-11). Pain intensity was defined as:
[0289] • Current pain: The intensity of pain currently being experienced
[0290] • Recalling pain: The maximum pain intensity experienced within the past 12-hour time interval.
[0291] Except for screening and day 0, postoperative pain was recorded in a digital diary for 90 days at the following specified times:
[0292] • On postoperative day 0, record current pain at 8:00 AM, 2:00 PM, 8:00 PM, and 2:00 AM on day 1 (if awake) in the applicable source file. During this period, record current pain immediately in the source file before taking any opioid remedies.
[0293] • From 8:00 a.m. on Day 1 until discharge (72 hours post-surgery, or at least 3:00 p.m. on Day 3, whichever is later), subjects recorded current pain and recalled pain in a digital diary at 8:00 a.m. and 8:00 p.m., and recorded current pain at 2:00 a.m. (if awake) and 2:00 p.m. During this period, current pain was recorded in the digital diary immediately before any opioid remedy was administered.
[0294] • For up to 14 days after discharge, participants recorded current pain and recalled pain in a digital diary at 8:00 AM and 8:00 PM, and recorded current pain again at 2:00 PM. During this period, current pain must be recorded immediately before taking any opioid remedy.
[0295] • From 15 to 90 days, current pain and recollection of pain were recorded in a digital diary at 8 a.m. and 8 p.m. during this period. Current pain was also recorded immediately before any opioid remedies were taken.
[0296] Non-routine concomitant medications and rescue medications were recorded in the source file up to 8:00 AM on Day 1, after which subjects entered all medications (including rescue medications) into a digital diary for 90 days.
[0297] Adherence to self-managed physical therapy and the need for walking aids were recorded in a digital diary for 90 consecutive days at 8 a.m.
[0298] Follow-up visits were conducted at 2 and 6 weeks post-surgery, and at 3, 6 (by phone), 9 (by phone), and 12 months.
[0299] At 72 hours, 2 weeks, and 6 weeks, and at 3 months and 12 months, effusion, skin temperature, and blood biomarkers (also measured at 24 and 48 hours, but not at 12 months) were measured to assess inflammation, while range of motion (ROM) assessed knee function. A timed stand-up walking test was performed at 2 weeks, 6 weeks, and 3 months. At each visit starting at 2 weeks, the Knee Society Knee Scoring System (KSS2011), the Short Form Health Questionnaire (SF-12v2), and EuroQoL (EQ-5D) were applied, and work status was collected.
[0300] Pain assessment
[0301] Table 2 shows the time-weighted NRS pain AUC scores over time for all patients or only for patients who had not previously received TKR, patients receiving F14 formulation combined with standardized multimodal analgesia (MMA) and patients receiving MMA alone.
[0302] Figure 4 This study shows the percentage difference in the least squares mean of NRS pain AUC between patients who had not previously received TKR and those who received F14 formulation combined with standardized multimodal analgesia (MMA) versus those who received MMA alone, statistically adjusted for opioid consumption.
[0303] Table 2: Time-weighted AUC of current NRS pain (adjusted for opioid use)
[0304]
[0305] It can be seen that, across all patients, from 3 days to 3 months post-TKR, patients receiving the F14 formulation combined with MMA consistently showed lower numerical differences in pain compared to those receiving MMA alone. However, in the subgroup of patients without TKR, there was a statistically significant difference in enhanced treatment efficacy and substantial pain reduction (at least a 10% difference in NRS pain AUC), which was statistically significant at 3 days and nearly significant at 7 days and 2 weeks.
[0306] The clinical studies that led to the approval of the commercial product Zynrelef (Heron) (a TKR postoperative analgesic) also demonstrated a similar magnitude of 10% NRS AUC difference, which is based on the generally accepted minimum clinically important difference (MCID) of 10-20% for pain (RH Dworkin, et al, “Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations, The Journal of Pain, Volume 9, Issue 2, 2008, Pages 105-121).
[0307] Opioid consumption
[0308] Figure 5 This graph shows the mean cumulative opioid consumption over time, in morphine milligram equivalents (MME), for all patients (top) and patients who had not previously received TKR (bottom), with patients receiving F14 formulation combined with standardized multimodal analgesia (MMA) (black circles) and patients receiving MMA alone (white circles). Significant differences in daily analgesic requirements became apparent at 2 weeks post-TKR, with the final difference in mean cumulative opioid consumption between patients receiving F14 formulation combined with MMA and those receiving MMA alone being approximately 6.4% for all patients and approximately 13.8% for patients who had not previously received TKR.
[0309] Patients receiving the F14 formulation combined with MMA consumed fewer opioids over 3 months and reduced their use more quickly than patients receiving MMA alone.
[0310] Table 3 shows that at 3 months post-surgery, fewer subjects in the F14+MMA group used opioid salvage therapy than those in the MMA-only group, which was almost statistically significant for all patients (5.6% vs 15.9%; p=0.0536) and for patients who had not previously received TKR (4.1% vs 13.5%; p=0.1212).
[0311] Table 3: Percentage of patients using opioids at 3 months
[0312]
[0313] knee joint range of motion
[0314] Figure 6AThis is a graph showing the change in knee range of motion (ROM, in degrees) over time for all patients (top) or only patients who have not previously received TKR (bottom), patients receiving F14 formulation combined with standardized multimodal analgesia (MMA) (black circle) and patients receiving MMA alone (white circle).
[0315] Figure 6B yes Figure 6A The enlarged version of the figure below shows the ROM (ROM) of patients who have not previously received TKR over a period of 2 to 12 weeks. The key baseline ROM (100°) required for recovery is indicated by the dashed line, which is the benchmark for recovery after TKR.
[0316] Range of motion (ROM) represents a direct measure of knee joint function, and a ROM greater than 100° is positively correlated with patient satisfaction. Patients are able to ride a stationary bike and resume daily activities such as climbing stairs, sitting, putting on socks, or lifting objects. A ROM less than 100° leads to patient dissatisfaction, slows rehabilitation, and limits daily activities.
[0317] Figure 6C A diagram showing how to measure ROM is provided.
[0318] Table 4A below provides values for knee range of motion (in degrees) for all patients and a subgroup of patients who have not previously received TKR.
[0319] Table 4A: Scope of Activities
[0320]
[0321] Patients receiving the F14 formulation combined with MMA showed improved knee range of motion at all postoperative time points compared to patients receiving MMA alone, which was highly significant and clinically relevant at 6 weeks, 3 months, and 12 months.
[0322] Table 4B shows the percentage of patients who achieved a ROM of 100° or higher 6 weeks after TKR, and demonstrates that the rate was statistically significantly higher in patients receiving the F14 formulation combined with MMA compared to patients receiving MMA alone.
[0323] Table 4B: Percentage of patients achieving 100° ROM
[0324]
[0325] Knee joint effusion
[0326] Figure 7This graph shows the change in knee joint effusion (percentage difference in circumference compared to the contralateral knee) over time for all patients (top) or only patients who have not previously received TKR (bottom), patients receiving the F14 formulation combined with standardized multimodal analgesia (MMA) (white circles) and patients receiving MMA alone (black circles). Patients randomized to F14 showed statistically significant improvements in joint effusion compared to MMA at 6 weeks (p=0.003), 3 months (p=0.020), and 12 months (p=0.023). Although no statistically significant difference was shown at 2 weeks, numerical improvements were observed in patients randomized to F14; the full results are listed in Table 5 below.
[0327] Table 5
[0328]
[0329] Timed Stand-Up-Walk Test (TUG)
[0330] Figure 8 The graph shows the time taken for the Timed Stand-Up-Walk (TUG) test over time for all patients (top) or only patients who have not previously received TKR (bottom), patients receiving the F14 formulation combined with standardized multimodal analgesia (MMA) (squares) and patients receiving MMA alone (circles).
[0331] Table 6 below provides TUG values for all patients and patients who have not previously received TKR.
[0332] Table 6: Timed Stand-Up and Walk Test
[0333]
[0334] Patients who were randomly assigned to F14 and had not previously received TKR had significantly shorter test completion times, approaching statistical significance at 2 weeks and significantly shorter at 6 weeks and 3 months.
[0335] Time to resume work
[0336] At 3 months post-surgery, more patients who received the F14 preparation and MMA returned to work than those who received MMA alone. The rate of return to work was even higher in the group of patients who had not previously received TKR (see Table 7).
[0337] Table 7: Time to Resume Work
[0338]
[0339] SF-12 v2 (Short-Term Health Survey)
[0340] The SF-12 is a validated self-reported outcome measure used to assess the impact of physical and mental health on an individual's daily life. It is commonly used as a measure of quality of life. At each time point, patients receiving the F14 preparation and MMA scored numerically better on all eight dimensions of the questionnaire than those receiving MMA alone. Table 8 below shows the physical function dimensions, and Table 9 shows the composite score, i.e., the total body composition (PCS):
[0341] Table 8: SF-12 Survey Results
[0342] Physical Functional Health Dimension
[0343]
[0344] Table 9: SF-12 Survey Results
[0345] PCS rating
[0346]
[0347] At 3 months post-surgery, patients receiving the F14 formulation and MMA showed substantial improvements across all dimensions, as well as on the PCS and the composite psychological component pool (MCS), as shown in Table 10:
[0348] Table 10: SF-12 survey results at 3 months
[0349]
[0350] EQ-5D-5L
[0351] EQ-5D is a standardized health status measurement developed by EuroQol, designed to provide a simple and universal health measurement method for clinical and economic assessment. A negative result indicates deterioration compared to baseline. Table 11 below provides values for all patients and patients who have not previously received TKR. A negative value at 2 weeks indicates deterioration compared to baseline in patients receiving MMA alone, while patients receiving both the F14 preparation and MMA showed better scores than their baseline scores.
[0352] Table 11: EQ-5D-5L Index Values
[0353]
[0354] 2011 Knee Society Score (KSS2011)
[0355] KSS2011 is a proven and reliable tool that combines objective and subjective scales (four in total). See Noble PC, Scuderi GR, Brekke AC, Sikorskii A, Benjamin JB, Lonner JH, Chadha P, Daylamani DA, Scott WN, Bourne RB. Development of a New Knee Society Scoring System. Clin Orthop Relat Res. 2011 It is one of the most commonly used methods for assessing patients with TKR. It is a validated system that combines objective components derived by the physician with those derived by the patient to assess pain relief, functional capacity, satisfaction, and achievement of expectations. Table 12 below provides results for all patients and those who have not previously undergone TKR.
[0356] Table 12: Results of the 2011 Knee Society Scores (KSS2011)
[0357] All TKR
[0358]
[0359] No TKR
[0360]
[0361] The "objective knee joint indicators" and "patient expectations" dimensions were comparable across groups. A comparative analysis was conducted on changes compared to screening.
[0362] Although the study did not reach statistical significance for its primary endpoint related to pain intensity, it demonstrated statistically significant improvements in inflammation-related outcomes (e.g., knee joint ROM, joint effusion) at 6 weeks and 3 months post-surgery, which is significant for the speed at which patients can regain function and return to normal daily activities. Numerical improvements were also identified at all time points, including the time to stand-up walking test, time to return to work at 3 months, SF-12, EQ-5D, and KSS2011 scores. Furthermore, when considering the large subgroup of patients in this study who had not previously received TKR, statistical significance was demonstrated for pain intensity on day 3, with numerical and sustained improvements in pain intensity at subsequent time points. Patients who had not previously received TKR and were randomized to F14 also showed reduced opioid consumption and additional improvements in all measurements of knee ROM, knee effusion, time to stand-up walking test (significant at 6 weeks and 3 months), time to return to work, SF-12, EQ-5D, and KSS2011 scores (significant at 2 weeks and 6 weeks on the Functional Activity Scale). Finally, this study demonstrated the excellent safety and tolerability of F14 in patients receiving TKR compared to the active control group.
[0363] Although the invention has been described according to various preferred embodiments, those skilled in the art will understand that various modifications, substitutions, omissions, and alterations can be made without departing from its scope. Therefore, it is intended that the scope of the invention be limited by the scope of the claims (including their equivalents).
Claims
1. A method for treating or managing pain or inflammation in a patient following total knee arthroplasty (TKR), the method comprising administering a biodegradable drug delivery composition to the patient's knee joint, the composition comprising: (a) Biodegradable triblock copolymers having the following formula: PLA v -PEG w -PLA x In the formula, v and x are the number of repeating units ranging from 24 to 682, w is the number of repeating units ranging from 4 to 273, and v = x or v ≠ x; (b) Biodegradable diblock copolymers having the following formula: mPEG y -PLA z In the formula, y and z are the number of repeating units, with y ranging from 3 to 68 and z ranging from 7 to 327. in, In the biodegradable pharmaceutical composition, the ratio of the biodegradable triblock copolymer of (a) to the biodegradable diblock copolymer of (b) is from 3:2 to 1:19; and (c) Nonsteroidal anti-inflammatory drugs (NSAIDs).
2. The method according to claim 1, wherein, The patient had not previously received TKR.
3. A method for treating or managing pain or inflammation in a patient after TKR, the method comprising administering a biodegradable drug delivery composition to the patient's knee joint, the composition comprising: (a) Biodegradable triblock copolymers having the following formula: PLA v -PEG w -PLA x In the formula, v and x are the number of repeating units ranging from 24 to 682, w is the number of repeating units ranging from 4 to 273, and v = x or v ≠ x; (b) Biodegradable diblock copolymers having the following formula: mPEG y -PLA z In the formula, y and z are the number of repeating units, with y ranging from 3 to 68 and z ranging from 7 to 327. in, In the biodegradable pharmaceutical composition, the ratio of the biodegradable triblock copolymer of (a) to the biodegradable diblock copolymer of (b) is from 3:2 to 1:19; and (c) Nonsteroidal anti-inflammatory drugs (NSAIDs) The patient had not previously received TKR.
4. The method according to any one of claims 1 to 3, wherein, In the composition, the NSAID is present in an amount of 1% to 85% (w% / w%), 1% to 60% (wt% / wt%), or 10% to 60% (wt% / wt%), or 10% to 30% (wt% / wt%), or 10% to 20% (wt% / wt%), or about 15% (wt% / wt%) of the total composition.
5. The method according to any one of claims 1 to 4, wherein, The polyethylene glycol chains in the triblock copolymers and / or diblock copolymers have a molecular weight range of 300 Da to 12 kDa, or 1 kDa to 8 kDa, or 1 kDa to 5 kDa, or 1 kDa to 2 kDa.
6. The method according to claim 5, wherein, The polyethylene glycol chains in the triblock copolymers and / or diblock copolymers have a molecular weight of 1.5 to 2.5 kDa, or about 2 kDa.
7. The method according to any one of claims 1 to 6, wherein, The molar ratio of lactic acid to ethylene oxide in the triblock copolymer is 1.6 to 7.2, or 1.6 to 5.0, or 1.6 to 3.0, or about 2.
0.
8. The method according to any one of claims 1 to 7, wherein, The molar ratio of lactic acid to ethylene oxide in the diblock copolymer is 1.6 to 7.2, or 1.6 to 5.0, or 1.9 to 4.8, or 1.9 to 3.0, or about 2.
4.
9. The method according to any one of claims 1 to 8, wherein, The molar ratio of lactic acid to ethylene oxide in the triblock copolymer is 1.6 to 7.2, and the molar ratio of lactic acid to ethylene oxide in the diblock copolymer is 1.9 to 4.
8.
10. The method according to any one of claims 1 to 9, wherein, The degree of polymerization in the triblock copolymer is 92 to 135, and the degree of polymerization in the diblock copolymer is 91 to 180; or, the degree of polymerization in the triblock copolymer is 95 to 130, and the degree of polymerization in the diblock copolymer is 95 to 175; or, the degree of polymerization in the triblock copolymer is 99 to 132, and the degree of polymerization in the diblock copolymer is 95 to 175; or, the degree of polymerization in the triblock copolymer is 100 to 170, and the degree of polymerization in the diblock copolymer is 115 to 195.
11. The method according to any one of claims 1 to 10, wherein, The triblock copolymer is present in an amount of 2% to 45% (wt% / wt%), or 6% to 24% (wt% / wt%), or 6% to 15% (wt% / wt%), 6% to 10% (wt% / wt%), or about 8% (wt% / wt%) of the total composition.
12. The method according to any one of claims 1 to 11, wherein, The diblock copolymer is present in an amount of 8% to 50% (wt% / wt%), or 12% to 40% (wt% / wt%), or 20% to 40% (wt% / wt%), or about 32% (wt% / wt%) of the total composition.
13. The method according to any one of claims 1 to 12, wherein, The triblock copolymer is present in an amount of 6% to 24% (wt% / wt%) of the total composition, and the diblock copolymer is present in an amount of 12% to 40% (wt% / wt%) of the total composition.
14. The method according to any one of claims 1 to 13, wherein, The total polymer content is 20% to 50% (w% / w%), or 30% to 50% (w% / w%), or about 40% (w% / w%) of the total composition.
15. The method according to any one of claims 1 to 14, wherein, The total polymer content is 30% to 50% (w% / w%) of the total composition, and the NSAID is present in an amount of 10% to 20% (w% / w%) of the total composition.
16. The method according to any one of claims 1 to 15, wherein, The composition also contains a pharmaceutically acceptable carrier.
17. The method according to claim 16, wherein, The pharmaceutically acceptable carrier is a biocompatible organic solvent.
18. The method according to claim 17, wherein, The biocompatible organic solvent is selected from: benzyl alcohol, benzyl benzoate, dimethyl isosorbide (DMI), dimethyl sulfoxide (DMSO), ethyl acetate, ethyl benzoate, ethyl lactate, glycerol formaldehyde, methyl ethyl ketone, methyl isobutyl ketone, N-ethyl-2-pyrrolidone, N-methyl-2-pyrrolidone (NMP), pyrrolidone-2, tetraethylene glycol, triacetin, glyceryl tributyrate, tripropionate (tripro), and mixtures thereof; in one embodiment, the solvent is DMSO, tripro, NMP, and mixtures thereof, optionally DMSO.
19. The method according to any one of claims 1 to 18, wherein, The NSAID is at least one of the following: etofenadine, celecoxib, alpracoxib, rofecoxib, nabumetone, benorilate, etoricoxib, ampicillin, aminopyrine, vardicoxib, acetaminophen, buphenoxylic acid, nimesulide, parecoxib, mefenamic acid, dextro ibuprofen, ibuprofen, flurbiprofen, aspirin, dextro ketoprofen, diclofenac, diflunisal, etoricoxib, fenofosoxim, fenofosoxim, indomethacin, ketoprofen, ketoroxylic acid, lornoxicam, loxoprofen, Loxomac, romecoxib, meclofenamic acid, meloxicam, naproxen, Naprosyn, nimaloxos, oxapazine, piroxicam, disalicylate, sulindac, tenoxicam, tofenamic acid, and ropivacaine.
20. The method according to claim 19, wherein, The NSAID mentioned is celecoxib.
21. The method according to claim 20, wherein, The composition comprises celecoxib in an amount of 13% to 17% (wt% / wt%) of the total composition, a triblock copolymer in an amount of 7% to 9% (wt% / wt%) of the total composition, a diblock copolymer in an amount of 30% to 34% (wt% / wt%) of the total composition, and dimethyl sulfoxide in an amount of 43% to 47% (wt% / wt%) of the total composition.
22. The method according to any one of claims 1 to 21, wherein, The formulation of the biodegradable pharmaceutical composition is prepared as follows: a triblock copolymer and a diblock copolymer are mixed in a biocompatible organic solvent to form a mixture of the triblock copolymer and the diblock copolymer; NSAID is added to the mixture of the triblock copolymer and the diblock copolymer.
23. The method according to any one of claims 1 to 22, wherein, The composition is administered to the patient in volumes of 0.1 to 6 mL, 2 to 5 mL, or 3 to 4 mL.
24. The method according to any one of claims 20 to 23, wherein, The celecoxib concentration of the composition is from about 150 mg / mL to about 200 mg / mL, or from about 170 mg / mL to about 190 mg / mL.
25. The method according to claim 24, wherein, Following a single administration of the composition, the maximum celecoxib plasma concentration reached 24 hours after TKR is less than 200 ng / mL, optionally less than 180 ng / mL, and optionally less than 160 ng / mL.
26. The method according to any one of claims 1 to 25, wherein, Following TKR, the release of therapeutically effective concentrations of NSAID lasts for at least 4 weeks, preferably at least 6 weeks.
27. The method according to any one of claims 1 to 26, wherein, The composition is a liquid that can be injected into the knee joint, or a solid particle that can be injected into the knee joint, or a rod-shaped implant, or a spatial formulation.
28. The method according to any one of claims 1 to 27, wherein, The method also includes the administration of standardized multimodal analgesia.
29. The method according to claim 28, wherein, The standardized multimodal analgesia comprises two or more active pharmaceutical ingredients selected from the following: bupivacaine, ropivacaine, lidocaine, acetaminophen, mesobamo, pregabalin, gabapentin, ketamine, morphine, oxycodone, hydrocodone, hydromorphone, fentanyl, tramadol, tapentadol, nerve blockers, and dexamethasone; or, the standardized multimodal analgesia comprises bupivacaine hydrochloride, acetaminophen, and mesobamo.
30. The method according to claim 29, wherein, Bupivacaine is administered via periarticular infiltration. For subjects weighing less than 80 kg, a mixture of 0.25% bupivacaine with adrenaline (1:200,000) and 0.25% bupivacaine without adrenaline is used at a ratio of 2:
1. For subjects weighing more than 80 kg, a mixture of 0.25% bupivacaine with adrenaline (1:200,000) and 0.25% bupivacaine without adrenaline is used at a ratio of 3:1, administered at a maximum of 90 mL per kg.
31. The method according to any one of claims 28 to 30, wherein, The standardized multimodal analgesia includes opioids; optionally, the opioids are selected from morphine, oxycodone, hydrocodone, hydromorphone, fentanyl, tramadol, tapentadol, and combinations thereof, or the opioids are morphine and / or oxycodone.
32. The method according to claim 31, wherein, Compared to patients receiving only standardized multimodal analgesia containing opioids, the patients' daily opioid consumption or average cumulative opioid consumption was reduced; optionally, the reduction occurred 2 weeks to 90 days after TKR, or within 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, or 90 days after TKR; or, at 90 days after TKR, the cumulative opioid consumption was reduced by 15% to 20%; or, for patients who had not previously received TKR, the cumulative opioid consumption was reduced by 25% to 30% at 90 days after TKR.
33. The method according to any one of claims 1 to 32, wherein, Compared to patients receiving only standardized multimodal analgesia, the area under the curve (AUC) of the digital rating scale (NRS) pain score was reduced at 3, 7, 2, 6, or 90 days after TKR; optionally, the reduction was calculated based on the least squares mean of the NRS AUC; or, compared to patients receiving only standardized multimodal analgesia, the least squares mean of the NRS pain score AUC was reduced by at least 3%, optionally at least 4%, optionally at least 5%, optionally at least 6%; or, for patients who had not previously received TKR, compared to patients receiving only standardized multimodal analgesia, the least squares mean of the NRS pain score AUC was reduced by at least 8%, optionally at least 9%, optionally at least 10%, optionally at least 12%, optionally at least 14%, optionally at least 16%.
34. The method according to claim 33, wherein, The AUC of the Numerical Rating Scale (NRS) pain score is adjusted based on opioid consumption.
35. The method according to any one of claims 1 to 34, wherein, Compared to patients who received only standardized multimodal analgesia, the patients had a reduced least-squares mean of the visual analog scale (VAS) for pain at 2 weeks, 6 weeks, or 90 days after TKR; optionally, the reduction was at least a 10% difference in the least-squares mean of the VAS, optionally at least a 20% difference.
36. The method according to any one of claims 1 to 35, wherein, Compared to patients who only received standardized multimodal analgesia, these patients had a shorter time frame to achieve a knee range of motion of 100 to 110 degrees.
37. The method according to any one of claims 1 to 36, wherein, Compared to patients receiving only standardized multimodal analgesia, the patients showed improved range of motion (ROM) at 1 week to 3 months after TKR, or at 1 week, 2 weeks, 3 weeks, 6 weeks, or 12 weeks after TKR; optionally, at 3 months after TKR, ROM improved by 5% to 10% compared to patients receiving only standardized multimodal analgesia.
38. The method according to any one of claims 1 to 37, wherein, The reduction in knee joint effusion in the patients was measured as a percentage difference in circumference between the knee that had undergone TKR and the contralateral knee, as well as between the knee that had undergone TKR and the patient who had received only standardized multimodal analgesia; optionally, the measurement was performed at 2 weeks, 6 weeks or 3 months after TKR.
39. The method according to any one of claims 1 to 38, wherein, Compared to patients receiving only standardized multimodal analgesia, the patients showed improved mobility as measured by the timed stand-up walking test, which measures the time required for a patient to stand up, walk 3 meters (10 feet), turn around, walk back and sit down again; optionally, the timed stand-up walking test results were measured 2 weeks, 6 weeks or 3 months after TKR.
40. The method according to any one of claims 1 to 39, wherein, The total score of body composition on the Short Form 12 Health Survey (SF-12v2) was at least 15% or at least 30% higher than that of patients who received only standardized multimodal analgesia.
41. The method according to any one of claims 1 to 40, wherein, Compared to patients who received only standardized multimodal analgesia, the patients showed improved health status as measured by the EuroQoL 5D (EQ-5D-5L) index at 2 weeks after TKR; optionally, the index increased by at least 70 or at least 85 compared to patients who received only standardized multimodal analgesia; or, in the case where the patients had not previously received TKR, the index increased by at least 150 or at least 170 at 2 weeks after TKR compared to patients who received only standardized multimodal analgesia.
42. The method according to any one of claims 1 to 41, wherein, Compared to patients receiving only standardized multimodal analgesia, the patients showed improvement in the 2011 Knee Society Score (KSS2011) measured 2 weeks after TKR; optionally, the patients showed an increase of at least 30%, at least 40%, or at least 50% in KSS2011 patient satisfaction and / or functional activity scores compared to patients receiving only standardized multimodal analgesia; or, compared to patients receiving only standardized multimodal analgesia, patients who had not previously received TKR showed an increase of at least 40%, at least 50%, or at least 60% in KSS2011 patient satisfaction and / or functional activity scores.
43. The method according to any one of claims 1 to 42, wherein, The biodegradable drug delivery composition is drawn into a syringe for administration and injected into the knee joint; or, the composition is manually formed into a solid mass by exposing it to an aqueous liquid and manually placing it into the knee joint.
44. The method according to any one of claims 1 to 43, wherein, The biodegradable drug delivery composition is subjected to mechanical action.
45. The method according to claim 44, wherein, The mechanical action is generated by the joint's internal structure, joint movement, weight-bearing, and / or synovial fluid pressure.
46. A composition for use in the method of any one of claims 1 to 45.
Citation Information
Patent Citations
Hydrogels containing triblock copolymers, and preparation and use thereof
US6350812B1
